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      Abstract 
This thesis collects the work I have done during the three-year of my PhD Course. During my 
first year I have started a path that has allowed me to acquire different techniques to set up 
and culture animal cell lines as well as to evaluate the cytotoxic and anti-picornavirus 
activities of a class of novel synthetic quinoxaline (Part I). Part of the second and all the third 
year was spent at the NIAID/NIH, Hamiltion MT, USA,  in the laboratory of persistent viral 
diseases under the supervision of dr. Bruce Chesebro investigating the effect of statins for the 
control of neuroinflammation (Part II).  
 
Part I - Antiviral activity of quinoxalines derivates as new leads against Picornavirus 
Aim: New quinoxaline derivatives were synthesized and tested for cytotoxicity and antiviral 
activity against human coxsackie virus B5 [CVB-5] and polio virus type-1 [Sb-1], focusing on 
the mode of action of the more potent compound Ethyl 4-[(2,3-dimethoxyquinoxalin-6-
yl)methylthio]benzoate (7a). Methods:Virus multiplication in Vero76 cells were monitored 
by plaque reduction assay. Time of addition assays were performed to determine the influence 
of the time of treatment on the antiviral activity. Initial steps of virus infection were dissected 
into adsorption and penetration steps by switching the incubation temperature from 4°C to 
37°C. Results: Four compounds (7a, 7b, 8a, 8b) showed a very potent antiviral activity 
(EC50s range 0.06-3.8 µM) against CVB-5. Compound 7a resulted the most active and 
selective derivative (SI >1000). Time of addition assays revealed that compound 7a interfered 
with the penetration/uncoating stage of the virus cycle. Conclusion: Further experiments to 
confirm the mechanism of action of the compoundare ongoing. 
 
Part II - In vitro studies on the anti-inflammatory activity of statins during 
neuroinflammation  
Aim: Due to the known pleiotropic activity of statins, Four different types of statins were 
investigated for their effect on the production of pro-inflammatory cytokines (IL-6 and 
CXCL10) in mouse and rat cortical microglia and astrocytes primary cultures. Methods: 
Primary cell cultures were obtained from 2 days old mice and Sprague-Dawley rats. The 
purity of the cell cultures was verified by immunofluorescence staining. The production of 
pro-inflammatory cytokines was stimulated by the mitogen LPS. The amount of cytokines 
produced in the absence and in the presence of statins was determined by using an 
extracellular protein kit specific for the cytokines analized. An MTT assay was performed in 
order to verify the viability of the cell cultures and to exclude a possible stimulation by statins 
themselves. Results: No LPS/stimulation and no statin/ cytokine inhibition was obtained in 
rat cells, while in mice derived cells, there was a good LPS stimulation and three out of the 
four statins inhibited of the production of IL-6 by mouse microglia.  
Conclusion: Statins seems to have a good anti-inflammatory activity on mouse cells, 
however, further studies should be performed in order to confirm these results. In rat cells, 
further studies should be performed in order to find better conditions of stimulation. In vivo 
testing of the effect of Atorvastatin and Simvastatin in mice affected by scrapie are ongoing.  
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PART I 
Antiviral activity of quinoxalines derivates as new leads against 
Picornavirus 
 
1. INTRODUCTION 
 
One of the major cause of morbidity and mortality in elderly people and young children are 
viral infections. Among them there are infections caused by human enteroviruses (HEVs), 
which are  pathogens circulating commonly in the environment, with a seasonal peak during 
early fall. The infection is normally asymptomatic or mild, but occasionally the virus spreads 
to secondary organs leading to more severe diseases such as aseptic meningitis or myocarditis 
(Kandolf et al., 1999; Rotbart, 1995). Enteroviruses, which include Coxsackie A and B, polio, 
and ECHO viruses, cause systemic infection in man after ingestion and replication in the 
gastrointestinal tract (Woodruff, 1980). They belong to the Picornaviridae family, 
characterized positive single-stranded RNA genomes that are translated as monocistronic 
polyproteins to rapidly generate mature viral particles (Lim et al., 2013).  
Coxsackieviruses are divided into group A and group B viruses based on early observations of 
their pathogenicity in mice, 23 serotypes of Coxsackie A viruses (CAV) and 6 serotypes of 
Coxsackie B viruses (CBV). Group A coxsackieviruses were noted to cause a flaccid 
paralysis, which was caused by generalized myositis, while group B coxsackieviruses were 
noted to cause a spastic paralysis due to focal muscle injury and degeneration of neuronal 
tissue; group B coxsackieviruses tend to infect the heart, pleura, pancreas, and liver, causing 
pleurodynia, myocarditis, pericarditis, and hepatitis. Coxsackie B viruses attach to target cells 
by receptors that are not shared with other members of the enteroviruses group. Thus all 6 
Coxsackie B viruses compete for the same receptor, while polioviruses attach to a different 
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receptor on target cells. A large number of particles (60-100) are required for infection of a 
cell and once absorption, uncoating, and penetration occurs, replication of new infectious 
particles is rapid. Replication is confined to the cytoplasm and is directed by the single-
stranded RNA genome that also serves as the messenger RNA for protein synthesis by the 
ribosomes (Fenner et al., 1974; Luria et al., 1978). Once the virus enters in the cells, 
macromolecular synthesis is rapidly suppressed; cell protein, RNA, and DNA synthesis are 
shut down after synthesis of viral-coded proteins. In particular, we worked on a Coxsackie B 
virus, Coxsackievirus B5(CVB-5) which is associated with several human diseases including 
encephalitis and myocarditis in immunocompromised children and CNS disease in older 
adults (Zhong et al., 2009).  
Until now, there has been no enterovirus-specific vaccine or therapeutic reagent available for 
clinical use (); there are some inhibitors that has been use on picornaviruses but they have not 
effect on entetrovirus-induced myocarditis. So, in an attempt to discover new antiviral agents 
for these infections, during this part of my work we investigated the antiviral activity of 
quinoxaline derivates against Coxsackievirus B5.  
Quinoxaline is also called as benzopyrazine. It is heterocyclic compound containing benzene 
ring and pyrazine ring (Patidar et al., 2011). Quinoxaline derivates are an important class of 
compound in which N replaces some carbon atoms in the ring of naphthalene. They are rare in 
natural state but their synthesis are easy to perform (Pereira et al., 2015). These compound 
seems to be interesting because they have been reported to show antibacterial, anticancer, 
antifungal, anti-inflammatory and antidepressant activities (Patidar et al., 2011).  
10 
 
 
Fig. 1: Chemical structure of quinoxaline derivatives 2a-d, 3-6, 7-10a,b 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
2. RESULTS 
 
Quinoxaline derivateswere tested in cell-based assays against two Picornaviridae, human 
enterovirus B [coxsackie virus B5, CVB-5] and human enterovirus C [polio virus type-1, Sb-
1]. Results are reported in Table 1. Four compounds (7a, 7b, 8a, 8b) showed a very potent 
antiviral activity (EC50s range of 0.06-3.8 µM) against CVB-5. Interestingly, 7a showed a 
very selective activity, with a selectivity index (SI)  >1000 and none cytotoxicity against all 
tested cell lines.  
The potential virucidal activity of  7a was investigated, incubating a CVB-5 solution 
containing 5x105 PFU/ml for 1 hour at 37°C with two concentrations (4 and 20µM). Tested 
compounds failed to affect the CVB-5 infectivity, suggesting that the inhibition of CVB-5 
replication observed in cell-based assays is not due to the infectivity inactivation of virions, 
but can be totally attributed to an interference of compounds with the viral life cycle. 
To investigate the mechanism of 7a on inhibition of CVB-5, we performed a time of drug 
addition experiment to determine at what stage of infection 7a inhibits (Fig.2). Pretreatment 
with 7a or addition of 7a simultaneously to infection, followed by the removal of the sample 
after two hours, does not reduce the virus titre. The sample addition, simultaneously or at 2 
hours post infection, significantly reduces the virus titre. The addition of sample at 4, 6, 8 or 
12 hours instead doesn’t reduce the virus titre, compared with the untreated control. These 
data suggest that 7a inhibits CVB-5 infection by targeting an early event of the life cycle, 
probably during the attachment or the entry of virus.  
12 
 
Tab. 1 Cytotoxicity and antiviral activity of Quinoxalines derivatives against Picornaviridae (CBV-5, Sb-1) 
viruses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCompd concn (µM) required to reduce the viability of mock-infected Vero-76 cells by 50%, as determined by the MTT 
method; 
bCompd concn (µM) required to reduce the plaque number of CVB-5 and Sb-1(c), by 50%, respectively, in Vero-76 cells.
Compds 
Vero76 CVB-5 Sb-1 
aCC50 bEC50 cEC50 
2a >100 >100 >100 
2b 75 >75 >75 
2c >100 >100 >100 
2d >100 >100 >100 
3 - - - 
4 >100 >100 >100 
5 - - - 
6 >100 >100 >100 
7a >100 0.09 >100 
7b >100 0.3 >100 
8a 65 0.06 >65 
8b 90 3.8 >90 
9a - - - 
9b >100 56 >100 
10a - - - 
10b >100 >100 >100 
    
Pleconaril >100 0.005 1.5 
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Fig. 2Time of drug addition experiment to determine at what stage 7a inhibits. The addition of sample 
simultaneously or at 2 hours post infection significantly reduces the virus titre. 
 
 
 
 
 
 
 
 
 
 
14 
3. CONCLUSIONS 
 
With the aim of developing new therapeutic agents against Enterovirus, important human 
pathogens that cause both acute and chronic diseases in infants, young children and 
immunocompromised individuals, we tested quinoxaline derivates against Coxsackievirus 
B5(CVB-5) and Sb-1. 
Unfortunately, none of compounds showed anti Sb-1 activity, but four of these derivatives 
resulted strongly active against CVB-5; in particular, 7a and 8a resulted endowed with 
potent and selective antiviral activity (EC50 = 0.09µM and 0.06 µM, respectively). Time of 
addition experiments suggest that 7a inhibits CVB-5 infection by targeting an early event 
during the life cycle.  
Coxsackieviruses type B is associated with several human diseases including encephalitis 
and myocarditis in immunocompromised children and CNS disease in older adults (Zhong et 
al., 2009) and unfortunately there has been no enterovirus-specific vaccine or therapeutic 
agents available for clinical use. Therefore, further studies are ongoing in order to better 
define the mechanism of action of 7a and 8acompounds. Overall, these findings may 
represent a good starting point for the development of novel and selective antiviral drugs for 
infections caused by Enterovirus, for which there is a continued need.  
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4. MATERIALS AND METHODS 
 
4.1 Quinoxaline derivates synthesis 
Quinoxaline derivatives 2a-d, 3-5 were prepared according to Scheme 1 while compounds 6, 
7-10a,b were prepared according to Scheme 2. The key intermediate 6-(bromomethyl)-2,3-
dimethoxyquinoxaline was prepared according to the procedures already described in the 
literature. Its reaction with thiophenole derivatives (1a-d) was carried out in DMFa at 70 °C 
to give the expected compounds 2a-d. From compound 2d via basic hydrolysis the 
corresponding carboxylic acid 3 was obtained. This compound was amidified with diethyl-
L-glutamate hydrochloride in DMFa, in presence of triethylamine (TEA) and diethyl 
dicarbonate (DEPC), to give derivative 4. The free acid 5 was finally obtained by alkaline 
hydrolysis. 
 
 
Scheme 1: synthesis of 2,3-dimethoxy-6-((phenylthio)methyl)quinoxaline derivatives 2a-d, 3-5. Reaction 
condition: i) DMFa, CsHCO3, 70 °C, 2h; ii) EtOH/H2O, NaOH 1M, 70 °C, 7h; iii) L-diethylglutamate, DMFa, 
DEPC, TEA, r.t., 2h; iv) EtOH, NaOH 1M, r.t., 3h. 
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Scheme 2: synthesis of 2,3-dimethoxy-6-((phenylthio)methyl)quinoxaline derivatives 6, 7-10a and 2,3-
dimethoxy-6-((pyridin-2-ylthio)methyl)quinoxaline derivatives 7-10b. Reaction condition: i) DMFa, r.t., 5 
days; ii) EtOH/H2O, NaOH 1M, 70 °C, 7h; iii) L-diethylglutamate, DMFa, DEPC, TEA, r.t., 2h; iv) EtOH, 
NaOH 1M, r.t., 3h.v) DMFa, CsHCO3, 70 °C, 2h; vi) EtOH, NaBH4, N2, r.t., 30 min 
 
4.2 Cells and viruses 
Cell lines were purchased from American Type Culture Collection (ATCC). Cell line 
supporting the multiplication of the RNA virus was Monkey kidney (Vero 76) [ATCC CRL 
1587 Cercopithecus Aethiops]. Viruses representative of ssRNA+ was Picornaviridae 
human enterovirus B [coxsackie type B5 (CVB-5), strain Ohio-1 (ATCC VR-29)] and 
Human Poliovirus type-1 Sabin (Sb-1) [strain Chat (ATCC VR-1562)]. 
 
4.3 Cytotoxity assay 
Vero-76 cells were seeded in 24-well plates at an initial density of 4x105 cells/mL, in 
Dulbecco’s Modified Eagle Medium (D-MEM) with L-glutamine and 25mg/L kanamycin, 
supplemented with 10% FBS. Cell culture was then incubated at 37 °C in a humidified, 5% 
CO2 atmosphere, in the absence or presence of serial dilutions of test compounds. Cell 
17 
viability was determined after 48-96 hrs at 37 °C by the crystal violet staining method for 
Vero-76. 
 
4.4 Antiviral assay 
Compound’s activity against CVB-5 was determined by plaque reduction assays in infected 
cell monolayers, as described earlier (Sanna et al., 2015). Briefly, Vero-76 monolayers were 
infected for 2 hours with 250 μL of proper virus dilutions; following removal of un-adsorbed 
virus, 500 μL of maintenance medium containing 0.75% methyl-cellulose, with or without 
serial dilutions of test compounds, were added. Cultures were incubated at 37°C for 3days 
and then fixed with PBS containing 50% ethanol and 0.8% crystal violet, washed and air-
dried. Plaques were then counted. The extent of cell growth/viability and viral multiplication, 
at each sample concentration tested, were expressed as percentage of untreated controls. 
Concentrations resulting in 50% inhibition (CC50 or EC50) were determined by linear 
regression analysis. 
4.5 Yield reduction assay 
Virus-infected cultures were incubatedwith antiviral compounds for a period sufficient to 
permit virus replication and thenassayed for the presence of new progeny virus by titration 
on separate monolayercultures.  
 
4.6 Time of drug addition 
In the time of drug addition experiments, Vero-76 cells were infected with CVB-5 at 0.3 
MOI. 7a at 1 µM was added at 2 h prior to infection, during the infection and at varying 
times post infection. The confluent monolayers of Vero-76 cells, seeded in 24-well tissue 
culture plates, were infected and incubated for 3 days as previously described. Monolayers 
were collected and the viral titre was determined by a plaque reduction assay. Medium 
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containing a ten-fold EC50 concentration of 7awas: i) added at -2 to 0 (pretreatment) and 
then removed; ii) added at the time of infection (time 0) and removed or maintained; iii) 
added at 2, 4, 6, 8 and 12 hours post infection. 
 
4.7 Virucidal activity assay  
This assay was carried out to determine whether 7a directly inactivated the CVB-5 virus. A 
CVB-5 suspension containing 5x105 PFU/ml was incubated with or without different 
concentrations of compounds for 1 hour at 37°C. At the end of incubation, the residual 
infectivity was determined by plaque reduction assay in Vero cells. 
 
4.8 Adsorption Assay 
Vero cells grown in 24-well plates were infected with CVB-5, with a m.o.i. of 0.3, in the 
presence or absence of compounds. Plates were incubated for 60 min at 4°C. Medium 
containing unadsorbed virus was then removed, cells were washed twice with PBS and 
covered with MEM containing 1% methylcellulose. Plaques were counted after 24 hrs of 
incubation at 37°C. 
 
4.9 Virus Penetration Assay 
Vero cells were infected with CVB-5 at a MOI of 0.3 at 4°C for 1hr.Cells were washed by 
ice-cold PBS or medium and then shifted to 37°C in the presence or absence of compounds. 
The effect of compounds at different concentrations were tested. After 2 hrs of virus 
penetration, un-penetreted virus was washed and inactivated by acid glycine buffer (8g of 
NaCl, 0.38 g of KCl, 0.1 g of MgCl2 .6H2O, 0.1 g of CaCl2 2H2O, and 7.5 g of glycine/L, 
pH adjusted to 3 with HCl). Then methylcellulose was added and plate was incubated at 
37°C for 24hrs.The amount of penetrated virus, which surviving the acid glycine treatment, 
was determined by plaque assay after 24 hrs. 
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PART II 
 
Study of anti-inflammatory activity of statins during neuroinflammation 
in vitro 
 
1. INTRODUCTION 
1.1 Neuroinflammation 
 
Neuroinflammation is becoming a very common problem. For a long time it was thought to 
be only a consequence of infectious diseases, but in the last few years it has become clear 
that neuroinflammation is part of the process that contributes to the degeneration of the 
central nervous system. While it is becoming clear that activation of microglia and astroglia 
and the attendant expression of proinflammatory cytokines and chemokines often are 
associated with disease-, trauma- and toxicant-induced damage to the CNS, it is by no 
means clear that a cause-and-effect relationship exists between the presence of a 
neuroinflammatory process and neural damage (O'Callaghan et al., 2008). 
Neuroinflammation is an inflammatory process that hits the central nervous system and it is 
caused by infections, traumas, toxic metabolites or autoimmunity. When one of these stimuli 
hits the CNS, the first type of response is the activation of glia cells, like microglia and 
astroglia.  
The inflammation is a process that is used as defense mechanism against pathogens or 
traumas. It includes distinct stages: first of all, there is the triggering event and the 
consequent molecular recognition by the cells of immune system (like microglia). These 
cells have different types of receptors on their cellular membrane that allow them to 
recognize different types of specific molecules on the surface of the pathogens. The 
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interaction between pathogen and receptor brings to the activation of a number of genes that 
encode cytokines and molecules involved in the phagocytosis. The most important role of 
cytokines is to stimulate other types of cells to produce chemical mediators of inflammation, 
which are responsible for the inflammatory response ( and for this reason they are called 
proinflammatory cytokines), but they can have also other functions (Pontieri G.M., 2012).  
The term “neuroinflammation” has come to denote chronic, CNS-specific, inflammation-
like glial responses that do not reproduce the classic characteristics of inflammation in the 
periphery but that may engender neurodegenerative events including plaque formation, 
dystrophic neurite growth and excessive tau phosphorilation (Streit et al., 2004). Cytokines 
can be useful at first, because they help to fight the pathogen but at the same time, when 
their action is particularly intense or extended for a long time, what would be a help for the 
organism can start to damage it. The protracted production of cytokines, for example, 
becomes detrimental for the cells of the CNS. These kind of molecules are produced by the 
glia cells for the purpose of recruiting mononuclear phagocytes in the developing brain 
(Rezaie et al., 1999), in CNS inflammation and in neurodegenerative diseases (Rezaie et al., 
2001). They are produced by glia cells but at the same time they go to activate them. After 
the activation, microglia start to proliferate and change their morphology, becoming rounded 
(ameboid) cells that are capable of moving faster throughout the CNS in order to find other 
pathogens; when microglia are activated they become phagocytes, to remove cellular debris 
of pathogens and CNS cells, and they start to increase the production of pro inflammatory 
cytokines. Also astrocytes activate during neuroinflammation but all the processes are not 
very clear; the activation of astrocytes is called “reactive gliosis” and we know that also 
these type of cells produces cytokines during this process.  
Neuroinflammation is generally considered a chronic inflammation, in which the cumulative 
ill effects of immunological microglial and astrocytic activation contribute to and expand the 
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initial neurodestructive effects, thus maintaining and worsening the disease process through 
their action (Streit et al., 2004). This situation is generally called “gliosis” which includes 
both microglial and astrocytic hyperactivation. One of the consequence of the chronic 
neuroinflammation is in fact the microgliosis; this process involves hyperactivated microglia 
that start to proliferate and also exogenous perivascular cells originating in the bone marrow, 
that migrate into the CNS after an injury, to help the microglia. In a chronic state of 
inflammation, these cells are over-activated and produce a number of molecules that can be 
toxic for the neuronal tissue, like pro-inflammatory cytokines, prostaglandin E2 and 
oxidative stress factors.  
As regards astrocytes, it is important to understand that with their endfeet they contibute to 
the formation of the Blood Brain Barrier (BBB), a barrier that separates the brain from the 
circulating blood, preventing the entrance in the CNS of toxic molecules and pathogens, 
under normal physiological conditions. Establishment, maintenance and repair of the 
endothelial barrier depend on pericytes and astrocytes and both are also linked to the 
disruption of the BBB (Argaw et al., 2012). When the astrocytes are activated in a condition 
of chronic inflammation, they undergo several changes which include the hypertrophy of 
cell bodies and glial processes, increased expression of proteins like GFAP, vimentin, nestin, 
tenascin-C and chondroitin sulfate proteoglycans (Cabezas et al., 2014; Alvarez et al., 2013). 
Moreover, they also start to produce a great amount of pro inflammatory cytokines that have 
a modulatory effect on microglia (Croisier and Graeber, 2006) and all these factors contibute 
to distrupte the BBB, which ceases to be a barrier and let toxic molecules, macrophages and 
lymphocytes spread into the CNS. Another brain damage after the activation of astrocytes is 
the formation of glial scars, which should be a mechanism to heal the brain but it could also 
bring detrimental effects. In fact, injury to the CNS induces tissue damage, which creates 
barriers to regeneration. One of the main barrier is the glial scar, which consists 
22 
predominantely of reactive astrocytes and proteoglycans. Axons can not regenerate beyond 
the glial scar, and they take on a dystrophic appearance of stalled growth (Silver and Miller, 
2004). In the acute phase, glial scar formation is crucial for sealing the lesion site to remodel 
the tissue, and temporally and spatially controlling the local immune response. The glial 
barrier seals off the area of damage to prevent further microbial infections and spread of 
cellular damage, maintains extracellular ion and fluid balance, prevents an overwhelming 
inflammatory and growth factor responses, as well as free radical scavenging. Furthermore, 
the glial scar stimulates revascularization of blood capillaries to increase the nutritional, 
trophic, and metabolic support of the nervous tissue (Huang et al., 2014).  
The glial scar produced after severe astrogliosis may separate necrotic tissue from healthy 
one, but also has the detrimental effect of impairing axonal regeneration through the 
expression of molecules like CSPGs, semaphorins and ephrin (Cabezas et al., 2014; Fitch 
and Silver 2008; Duffy et al., 2009).  
It is easy to understand that neuroinflammation and brain injuries are connected and the first 
feeds the last and viceversa. It is also clear that neuroinflammation can be a possible target 
for the treatment of several brain injuries like neurodegenerative disease.  
 
 
1.2 Glia cells and neuroinflammation  
 
The central nervous system includes, in addition to neurons, the Glial cells - or Glia – which 
are quite different from nerve cells. For a long time, they were thought to be only supportive 
cells and that they had little influence on information processing; this opinion is now 
changed (Silverthorn 2010). Glia are more numerous than nerve cells in the brain, 
outnumbering them by a ratio of perhaps 3 to 1. Although glial cells also have complex 
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processes extending from their cell bodies, they are generally smaller than neurons, and they 
lack axons and dendrites (Purves et al., 2001). There are different types of glial cells, but the 
most important are microglia, astrocytes and oligodendrocytes. Microglia have a different 
origin, being cells belonging to the immune system; their role is to protect the SNC from 
pathogens, toxic molecules and other factors that can be dangerous for the brain. Astrocytes 
are the most abundant type of glial cells, being almost 50% of the brain cells. They have 
numerous projections that take contact with neurons and with blood vessels, in this way the 
astrocytes provide nutrition to nerve cells. Besides, they provide neurons with substrates for 
the ATP synthesis, contribute to maintaining the extracellular homeostasis by absorbing K+ 
ions and water molecules, and they are also part of the Blood Brain Barrier thanks to their 
processes (Silverthorn 2010). Finally, oligodendrocytes are the cells that provide support 
and isolation to axon by producing myelin. For my thesis project I used two of these types of 
glial cells, Microglia and Astrocytes. 
 
 
1.2.1Microglia 
 
Microglia were discovered and characterized for the first time between 1919 and 1921 by 
the Spanish neuroscientist Pio del Rio Hortega. In 1932 he wrote a chapter called “Microglia” 
for the book Cytology and Cellular Pathology of the Nervous System,  in which he described 
microglia as cells that enter the brain during early development; that have amoeboid 
morphology and are of mesodermal origin; that they use vessels and white matter tracts as 
guiding structures for migration and enter all brain regions; that they transform into a 
branched, ramified morphological phenotype in the more mature brain; in the mature brain, 
they are found almost evenly dispersed throughout the central nervous system and display 
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little variation; each cell seems to occupy a defined territory;  after a pathological event, 
these cells undergo a transformation; transformed cells acquire amoeboid morphology 
similar to the one observed early in development; these cells have the capacity to migrate, 
proliferate and phagocytose (Kettenmann et al., 2011). This is how the microglia could be 
described even now.   
Microglia are the resident mononuclear phagocytes of the central nervous system, belonging 
to the glial system of non-neuronal cells that support and protect neuronal functions 
(Ginhoux at al., 2013).   
Originally, microglia were thought to originate in the bone marrow; instead these cells take 
origin from embryonic hematopoietic precursors in the extra-embryonic yolk sac (YS) and 
then they migrate in the CNS prior to birth. It seems that the cells that derive from the bone 
marrow are recruited after an injury or in reaction to inflammation to help the microglia in 
the CNS. However it is not clear yet if these cells persist and become integrated or are a 
temporary addition to the endogenous population (Ginhoux et al., 2013). In humans, from 
4.5 weeks of gestation, ameboid microglial cells were seen to enter the cerebral wall from 
the ventricular lumen and the leptomeninges (Rezaie et al., 2005; Monier et al., 2007). Once 
in the brain, they differentiate into “fetal macrophage population” even before the onset of 
monocyte production by the fetal liver (Naito et al., 1990).  
Microglia can have different shapes depending on their location and on the role. In a healthy 
brain they are called “resting microglia”, though they are always active, in every moment; in 
this case they have a ramified morphology, a small soma with fine cellular processes 
(Kettenmann e al., 2011). Various studies using two-photon microscopy have shown that 
ramified microglia are not "resting", as it has long been thought, but instead they are very 
motile cells that constantly move their processes (Davalos et al., 2005; Nimmerjhan et al., 
2005; Vinet et al., 2012). Under this condition they display a striking down-regulated 
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phenotype with low expression of CD45, Fc receptors and MHC class II (Perry and Teeling, 
2013). Microglia constantly screen their microenvironment, making them the sentinels of the 
CNS. Their processes are very sensitive to any change of brain homeostasis; infection, 
trauma, ischemia, neurodegenerative diseases, or altered neuronal activity, that is any 
disturbance or loss of brain homeostasis indicating real or potential danger to the CNS can 
evoke rapid and profound changes in the microglial cell shape, gene expression and the 
functional behavior which summarily is defined as “microglial activation” (Kettenmann e al., 
2011). 
When they become active, they undergo many changes, for example alterations in their 
morphology, such as hypertrophy of the cell soma, increased branching, upregulation or de 
novo synthesis of cell surface or intracellular molecules, and proliferation (Perry and 
Teeling, 2013). They assume a conformation called “ameboid”, in which the processes are 
shorter and they have a rounded shape. Local densities of microglia can also increase by 
proliferation, to provide more cells for the defense against invading germs and to organize 
for the protection and restoration of tissue homeostasis. Induction and rearrangement of 
surface molecules for cell-cell and cell-matrix interactions, changes in intracellular enzymes 
as well as release of multiple factors and compounds with pro-inflammatory and 
immunoregulatory effects are additional elements of the activation process. Microglia can 
unfold their phagocytotic activities to clear tissue debris, damaged cells, or microbes. 
Release of chemoattractive factors recruits and guides immune cell populations to the CNS, 
and presentation of antigens to T cells can subsequently aid the adaptive immunity in fight 
against viral or bacterial invasion. Gerhmann and colleagues, after inducing ischemia in rats, 
saw that microglial cells showed an increased expression of cellular markers such as the 
MUC 101- and the MUC 102 determinant and the CR3 complement receptor, recognized by 
the OX-42 antibody. These cellular markers are already found on resting microglial cells 
26 
and are known to be increased on activated microglial cells in other pathologies (Gerhmann 
et al., 1992).  
In a 2002 work, Combrinck and colleagues injected bacterial lipopolysaccharide (LPS) into 
mice affected by prion disease to mimic a peripheral infection and they showed that prior 
priming of microglia by the degenerative process, followed by further activation through 
signaling from the periphery, resulted in increased brain IL-1β synthesis and the consequent 
acute sickness behavioural responses (Combrinck et al., 2002). In another interesting work, 
a group used cultured BV-2 mouse microglia activated with DA quinone, HIV TAT protein 
and LPS to understand the gene expression when microglia are stimulated and activated and 
they found that a total of 9882 annotated genes were scored as present in resting microglia; a 
panel of 116 common genes was increased in expression by all three activating conditions: 
these genes included cytokines IL-1α, IL-1β, and IL-6, a number of chemokine genes, Nos2, 
Gch1, Mmp13, as well as Tnf receptor 5. Increased production of cytokines and chemokines 
would drive inflammatory processes and could act in a feed-forward manner to enhance and 
perpetuate microglial activation. The increase in Gch1 would synthesize increased levels of 
tetrahydrobiopterin, an essential cofactor for Nos2, thereby allowing heightened or sustained 
production of nitric oxide (Thomas et al., 2005). So, among the genes that are upregulated, 
many of them encode cytokines and chemokines, which are also produced by microglia in 
resting conditions, but during the neuroinflammation the over production of these molecules 
can worsen the condition. Stimulation rapidly induces cyto/chemokine gene transcription 
and effective release while intracellular protein amounts remain mostly very low. Members 
of the IL-1 family may exist as preformed precursors, allowing instant conversion and 
release of mature cytokine upon stimulation (Fassbender et al., 2000, Hanisch, 2002). The 
most important cytokines produced by activated microglia are:  
• IL-1, where IL-1α is the cell-associated form and IL-1β is the soluble form; its targets are 
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T- and B-cells, monocytes, and macrophages/microglia. Activated microglia can serve as 
major sources upon infection, ischemia, stroke, excitotoxicity, and mechanic injury (Hanisch, 
2001a) and suppression of endogenous IL-1 has thus often neuroprotective effects.  
• IL-6, which can be produced by a various cell types, including activated microglia. Like 
IL-1 and TNFα, IL-6 is considered a proinflammatory cytokine acting in the initiation and 
coordination of inflammatory responses and limiting the spread of infectious agents. 
• TNFα, which is produced by neurons, astrocytes and microglia (on injury, activated 
microglia is an early and prominent source of TNFα) (Gabay et al., 1997).  TNFα seems to 
have direct toxic effects on neuronal structures and myelin; apparently, low levels of TNFα 
have neuroprotective consequences, whereas high levels can cause destructive outcomes. 
( Hanisch, 2002).  
Microglia can produce also GROα (KC), MIP-1α, MIP-1β, MIP-2, MCP-1, RANTES, IP-10, 
and IL-8 in response to experimental stimulation by bacterial agents,  Aβ peptides, as well as 
cytokines, such as TNFα and IL-1. ( Hanisch, 2002).  
What is the purpose of cytokine production? They can activated other types of cells, like 
astrocytes and endothelial cells. Activation of astrocyte, for example, is needed for 
reestablishment of tissue integrity following injury; astrogliosis and glial scar formation are 
needed to close wounds, to wall off necrotic areas, and to stabilize regions of neural injury 
(Hanisch, 2002). Therefore, the cytokine release is an important process for the restoration 
of CNS functions, but in a condition of inflammation there is an overproduction of these 
molecules and this overproduction becomes detrimental for the brain itself. For example, 
activated microglia also produce nitric oxide and oxygen intermediate which are cytotoxic at 
high concentrations. Other microglial mediators can induce secondary reactions in 
endogenous or infiltrated cells, which are harmful for neuronal structures or interfere with 
their signaling. Microglia can stimulate lymphocytes by (re)presenting antigens in 
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conjunction with co-stimulatory signals and the release of cytokines. However, excessive 
recruitment of these microglial functions certainly has a profound impact on detrimental 
neuroinflammation and autoimmune defects ( Hanisch, 2002).  
 
1.2.2 Astrocytes 
 
Astrocytes (astron, star) are ramified glial cells that seems to constitute 50% of the brain 
cells, distributed throughout the brain and the spinal cord. The first scientist who spoke 
about glia cells was Rudolf Virchow in 1858, who said that neuroglia was a “substance… 
which lies between the proper nervous parts, holds them together and gives the whole its 
form in a greater or lesser degree”.But it was with Camillo Golgi and his black staining 
reaction that it was possible to see the morphological details of these cells; Golgi described 
stellate neuroglial cells and found that some glial cells (which were to all probability the 
protoplasmic astrocytes) send the processes to the blood vessels, where they establish the 
endfeet structures; he developed a concept of nutritive role of glia and suggested that glial 
cells establish the metabolic link between blood vessels and the brain parenchyma. Santiago 
Ramόn y Cajal developed the first specific stain for astrocytes, the gold chloride-sublimate 
technique, which, as we know today, labeled glial fibrillary acidic protein (GFAP). Using 
this technique Cajal confirmed the origin of astrocytes from radial glia, and also 
demonstrated that astrocytes can divide in the adult brain, thus laying the basis for much 
later discoveries of the stem properties of astroglia (Parpura and Verkhratsky, 2012). Finally, 
in 1891  Michael von Lenhossek gave them the name of “astrocyes”. 
Astrocytes are divided in various groups, forming a network in which they can communicate 
through junctions. Astrocytes have many functions; for a long time they were thought to 
have only support function, but they connect to the neuron through synapses, for the 
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exchange of chemicals, they provide substrates to neurons for the ATP production and 
contribute to maintain homestasis by absorbing K+ ions and water molecules. Finally, their 
processes surround blood vessels, forming the  Blood Brain Barrier (Silverthorn 2010). 
Astrocytes are traditionally divided into protoplasmic and fibrous types based on their 
morphologic appearance and distribution in the central nervous system (CNS). In most 
instances, protoplasmic astrocytes predominate in gray matter and fibrous astrocytes are 
most common in white matter (Montgomery, 1994). Protoplasmic astrocytes are found 
throughout all gray matter and exhibit a morphology of several stem branches that give rise 
to many finely branching processes in a uniform globoid distribution; fibrous astrocytes 
exhibit a morphology of many long fiber-like processes (Sofroniew and Vinters, 2010). 
Glial cells (astrocytes and oligodendrocytes) are generated from radial glia cells in the 
ventricular zone and subventricular zone. During CNS development, neurogenesis precedes 
gliogenesis, with radial glial serving as both the scaffolding for migration and the neural 
stem cell (NSC) substrate for both cell types (Chaboud and Deneen, 2013); the peak of 
astrogliogenesis occurs late prenatal to early postnatal stages, that is, E18-P7 in various 
rodent CNS regions (Yang e al., 2013). Adult astrocytes, regardless of their anatomical 
location (gray or white matter), typically occupy a large and non-overlapping domain, which 
is composed of a large number of branches and fine processes (Bushong et al., 2002).  
Although not all astrocytes express this specific marker, glial fibrillary acidic protein 
(GFAP), an intermediate filament protein expressed in astrocytes, is typically used to 
distinguish and identify astrocytes within the central nervous system (Oberheim et al., 2012).  
Expression of glial fibrillary acid protein (GFAP) has become a prototypical marker for 
immunohistochemical identification of astrocytes (Sofroniew et al., 2010).  GFAP was first 
isolated as a protein highly concentrated in old demyelinated plaques from multiple sclerosis 
patients and was then found to be associated immunohistochemically with reactive 
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astrocytes in such plaques and in other pathological contexts (Eng et al., 2000). However, 
GFAP is not an absolute marker of all non-reactive astrocytes and is often not 
immunohistochemically detectable in astrocytes in healthy CNS tissue or remote from CNS 
lesions. Although GFAP is immunohistochemically detectable in many astrocytes 
throughout the healthy CNS, it is clear from double staining with multiple markers 
(including transgenic reporter proteins) that many mature astrocytes in healthy CNS tissue 
do not express detectable levels of GFAP and that GFAP expression by astrocytes exhibits 
both regional and local variability that is dynamically regulated by a large number of inter- 
and intra-cellular signaling molecules (Sofroniew, 2009; Sofroniew et al., 2010).  
Astrocytes, by virtue of numbers and relationships with other structural and cellular 
components, play a diverse and vital part in development and normal functioning of the 
CNS: 
• Neuronal migration: It seems that neurons migrate along the processes of astrocytes during 
their development. Immunocytochemical studies have shown that the processes of radial glia 
contain vimentin and glial fibrillary acidic protein; these cells are believed to be immature 
astrocytes. Dur- ing further maturation of the CNS, these cells lose vimentin and 
differentiate into astrocytes after neuronal migration is complete (Montgomery, 1994).  
• CNS development: Astrocytes are important for the development of CNS, for example 
molecular boundaries formed by astrocytes take part in guiding the migration of developing 
axons and certain neuroblasts (Powell and Geller, 1999). Substantive evidence is 
accumulating that astrocytes are essential for the formation and function of developing 
synapses by releasing molecular signals such as thrombospondin (Barres 2008, 
Christopherson et al., 2005, Ullian et al., 2001).  
• Extracellular matrix proteins and adhesion molecules : Astrocytes are the major source of 
extracellular matrix proteins and adhesion molecules in the CNS. These molecules are 
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important in the development and maintenance of structural relationships (Montgomery, 
1994). 
• Regulation of blood flow:  Recent findings show that astrocytes produce and release 
various molecular mediators, such prostaglandins (PGE), nitric oxide (NO), and arachidonic 
acid (AA), that can increase or decrease CNS blood vessel diameter and blood flow in a 
coordinated manner (Gordon et al., 2007; Iadecola and Nedergaard, 2007; Sofroniew and 
Vinters, 2010). Moreover, thanks to their processes which are in contact with blood vessels 
and synapses, they can titrate blood flow in relation to levels of synaptic activity ( Sofroniew 
and Vinters, 2010).  
• Angiogenesis: Angiogenesis is the physiological process through which new blood vessels 
form from pre-existing vessels. Steps involved in angiogenesis include endothelial activation, 
basement membrane dissolution, replication and migration of endothelial cells to form cords 
and tubes, and maturation with reconstitution of the basement membrane. Astrocytes 
apparently are involved in at least some stages of angiogenesis and this may be important in 
repair of the CNS (Montgomery, 1994). 
• Brain homeostasis: astrocytes are important for the maintenance of the fluid, ions, pH and 
transmitter homeostasis of the synaptic interstitial fluid. Astrocytes processes are rich in 
aquaporin 4, which is a water channel; this channel play a critical role in regulating fluid 
homeostasis in the CNS (Sofroniew and Vinters, 2010).  
• Constitution of Blood Brain Barrier (BBB): The Blood Brain Barrier is a highly selective 
barrier that separates the circulating blood from the brain and allows to control the 
molecules that enter the CNS, leaving out potential toxic molecules or pathogens. The 
barrier also plays an important role in the homeostatic regulation of the brain 
microenvironment necessary for the healthy function of the CNS (Abbott, 2002). The BBB 
is formed by endothelial cells that form tight junctions and are surrounded by a basal lamina, 
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pericytes and astrocyte end-feet. With their end-feet, astrocytes are believed responsible for 
the formation of the tight junctions between endothelial cells (Montgomery, 1994). In a 
study of 1997, a group showed that cultured astrocytes implanted into areas with normally 
leaky vessels were able to induce tightening of the endothelium, indicating that astrocytes 
were a major source of the inductive influence from neural tissue (Janzer and Raff, 1997). 
Other studies suggest a role for astrocytes in regulating BBB properties of cerebral 
endothelial in vivo in adult mice through specific BMP signaling mechanisms on astrocyte 
endfeet that when disrupted cause BBB leaks (Araya et al., 2008; Sofroniew and Vinters, 
2010). It is clear, thus, that the role of astrocytes in the constitution of the BBB and their 
activation, in particular, is fundamental in the process of neuroinflammation.  
Like microglia, also astrocytes are important during an insult to the CNS, since they start a 
response which serves to limit the areas of damage and for the post-insult remodeling and 
recovery of neural function; this response is called “reactive astrogliosis”. Astrocytes 
respond to all forms of CNS insults such as infection, trauma, ischemia and 
neurodegenerative disease by a process commonly referred to as reactive astrogliosis, which 
involves changes in their molecular expression and morphology, and in severe cases, scar 
formation (Sofroniew, 2009). What happenes when astrocytes are stimulated and activated? 
They undergo through a process of hypertrophy and proliferation, in which there is a 
dramatic increase in glial fibrils throughout the cytoplasm and the increased width, length, 
number, and complexity of the processes. As a result, the cell bodies and processes enlarge, 
become increasingly eosinophilic, and may even be visible with hematoxylin and eosin 
(Montgomery, 1994).  The changes undergone during reactive astrogliosis have the potential 
to alter astrocyte activities both through gain and loss of functions that can impact both 
beneficially and detrimentally on surrounding neural and non-neural cells (Sofroniew, 2009). 
Astrocytes have the potential under different conditions of stimulation to produce 
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intercellular effector molecules of many different categories, or to alter their expression of 
molecules involved in all aspects of cellular activity including cell structure, energy 
metabolism, intracellular signaling and membrane transporters and pumps (Sofroniew, 
2009).  
Primarily, there is the up regulation of expression of GFAP and the body hypertrophy but 
not astrocyte proliferation,  however, the up regulation of GFAP expression in astrocytes 
that do not express detectable levels of GFAP in healthy tissue can lead to the staining of 
more cells, sometimes giving the false impression of proliferation (Sofroniew and Vinters, 
2010). If the triggering mechanism is able to resolve, then mild or moderate reactive 
astrogliosis exhibits the potential for resolution in which the astrocytes return to an 
appearance similar to that in healthy tissue (Sofroniew, 2009). But if the pathogen, or 
whatever caused the reaction of astroglia, does not resolve, the astrogliosis keeps getting 
worse. In this case, besides the hypertrophy of cell body and the up regulation of GFAP, 
astrocytes start to proliferate; finally there is the formation of the glial scar, which is a 
barrier formed by reactive astrocytes, microglia, endothelial cells and basal membrane and 
act as neuroprotective barrier to inflammatory cells and infectious agents, and that they form 
in particular along borders to severe tissue damage, necrosis, infection or autoimmune-
triggered inflammatory infiltration (Sofroniew and Vinters, 2010). In the acute phase, glial 
scar formation is crucial for sealing the lesion site to remodel the tissue, and temporally and 
spatially controlling the local immune response. The glial barrier seals off the area of 
damage to prevent further microbial infections and spread of cellular damage, maintain 
extracellular ion and fluid balance, prevent an overwhelming inflammatory and growth 
factor responses, as well as free radical scavenging (Rolls et al., 2009). Some studies have 
focused on ablation of proliferating scar-forming astrocytes, where it was used a model  
based on the transgenically targeted expression of herpes simplex virus thymidine kinase 
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(HSV-TK) specifically to astrocytes, which renders dividing astrocytes vulnerable to the 
antiviral drug ganciclovir; they found that loss or dysfunction of reactive astrocytes leads to 
a prolonged increase in leukocyte infiltration, failure of BBB repair with vasogenic edema, 
neuronal degeneration, and increased outgrowth of nerve fibers in injured CNS parenchyma 
(Bush et al., 1999). The glial scar also acts as an impediment to axon regeneration and thus 
prevents the recovery of CNS function in the chronic phase, because the reactive astrocytes 
secrete several growth-inhibitory molecules that chemically prevent axonal extensions 
(Huang et al., 2014). There are many triggers of reactive astrocytes and glial scar, like a 
number of cytokines, nitric oxide, neurotransmitters, that can be produced by many brain 
cells like neurons, microglia, oligodendrocyte lineage cells, pericytes, endothelia, and other 
astrocytes, in response to all forms of CNS insults (Sofroniew et Vinters, 2010). Molecular 
triggers that lead to proliferation of reactive astrocytes in vivo include EGF, FGF, endothelin 
1, and ATP (Gadea et al., 2008; Levinson et al., 2000; Neary and Zimmermann, 2009).  
During astrogliosis, activated astrocytes produce a number of different molecules with either 
pro- or anti-inflammatory potential, like cytokines (Eddleston and Mucke, 1993; John et al., 
2003) and they can exert both pro- and anti-inflammatory effects on microglia. How is it 
possible to have both effects? For example, astrocytes can exert different activities at 
different times after insults, or in different geographical locations in relation to lesions. So, 
reactive astrocytes may exert pro-inflammatory roles at early times after insults and in the 
center or immediate vicinity of lesions, but exert anti-inflammatory roles at later times and at 
the borders between lesions and healthy tissue (Sofroniew and Vinters, 2010).  
Among the many functions of astrocytes there is the constitution of the blood brain barrier; 
when astrocytes undergo astrogliosis, the blood brain barrier inevitably suffers damage. 
Several processes may affect the integrity of the BBB, including an increase in ROS 
production, elevated levels of proinflammatory cytokines,  and other toxic substances 
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(Cabezas et al., 2014) and many of these molecules are produced during neuroinflammation 
by microglia and astrocytes. All these triggers bring to the disruption of the BBB and its 
breakdown leads to edema, metabolic imbalance, excitotoxicity, and ingress of factors that 
potentiate inflammation and inhibit repair and facilitates infiltration of T and B lymphocytes, 
macrophages, and neutrophils (Argaw et al., 2012).  
 
1.3 Cytokines 
 
Cytokines are a class of small proteins that act as signaling molecules at picomolar or 
nanomolar concentrations to regulate inflammation and modulate cellular activities such as 
growth, survival, and differentiation (Vilcek, 2003). Cytokine is a general name; other 
names include lymphokine (cytokines made by lymphocytes and attract other immune cells 
like macrophages and othe lymphocytes to an infected site), monokine (cytokines made by 
monocytes), chemokine (cytokines with chemotactic activities), and interleukin (cytokines 
made by one leukocyte and acting on other leukocytes). Cytokines may act on the cells that 
secrete them (autocrine action), on nearby cells (paracrine action), or in some instances on 
distant cells (endocrine action)(Zhang and An, 2007).  The binding of a cytokine or 
chemokine ligand to its cognate receptor results in the activation of the receptor, which in 
turn triggers a cascade of signaling events that regulate various cellular functions such as 
cell adhesion, phagocytosis, cytokine secretion, cell activation, cell proliferation, cell 
survival and cell death, apoptosis, angiogenesis, and proliferation (Devi, 2005). In the 
nervous system, cytokines and chemokines function as neuromodulators and regulate 
neurodevelopment, neuroinflammation, and synaptictransmission (Ramesh et al., 
2013). .Cytokines and chemokines are crucial to the brain’s immune function serving to 
maintain immune surveillance, facilitate leukocyte traffic, and recruit other inflammatory 
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factors (Takeshita and Ransohoff, 2012).  
Among their functions, they activate inflammation; upon stimulation by pathogens or toxic 
molecules, immune cells as well as cells of the nervous system such as microglia (the 
resident macrophages of the brain), astrocytes, oligodendrocytes, the myelinating cells of the 
CNS, and Schwann cells in the peripheral nervous system (PNS), endothelial cells of the 
brain microvasculature, and even neurons can release cytokines and chemokines as well as 
respond to them by way of cytokine and chemokine receptors (Ramesh et al., 2013).  
Cytokines can be both pro-inflammatory, which promote inflammation, and anti-
inflammatory which suppress the activity of pro-inflammatory cytokines; some pro-
inflammatory molecules are: 
IL-8, which activates neutrophils to degranulate and cause tissue damage; IL-1 and TNF, 
which are inducers of endothelial adhesion molecules, essential for the adhesion of 
leukocytes to the endothelial surface prior to emigration into the tissues (Dinarello, 2000); 
IFN-α, produced by leucocytes and involved in innate immune response against viral 
infection; IFN-γ, generated by both innate and acquired immune cells, particularly T cells 
and NK cells and which can promote Th1 polarization, facilitate specific cytotoxicity by 
increasing the expression of MHC class-I and -II molecules, and boost antigen processing 
and immunoglobulin switching (Su et al., 2012); IL-23, which is heterodimeric cytokine 
composed of a p19 subunit and a p40 unit shared with IL-12 and it is produced by antigen 
presenting cells. IL-23 affects IFN-γ production, stimulates Th1-cell responses, activates 
memory T cells, and enhances inflammation by stimulating the production of 
proinflammatory cytokines. IL-23 is also essential to promote the expansion and survival of 
IL-17- producing cells (Riol-Blanco et al., 2010); IL-17, which has multiple functions in the 
regulation of tissue inflammation. There are 6 different IL-17, named IL-17A to IL17F (Su 
et al., 2012). IL-17 has a key role in tissue neutrophil recruitment and helps the clearance of 
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pathogens such as extracellular bacteria. IL-17 is produced by several cell types including 
activated T-cell subsets (CD4+, CD8+, CD4− CD8−, γδT cells), natural killer cells, and 
neutrophils (Dong, 2006).  
Among anti-inflammatory cytokines there are: IL-1ra, produced by monocytes and 
macrophages, is a 152-amino-acid protein that functions as a specific inhibitor of the two 
other functional members of the IL-1 family, IL-1α and IL-1β (Dinarello, 1996; Dinarello 
1998). IL-1ra,  IL-1α and IL-1β are very similar, IL-1ra shares approximately 26% amino 
acid sequence homology with IL-1b and 19% homology with IL-1a and the genes that 
encode these proteins are very close, on the long arm of chromosome 2 (Dinarello, 1996; 
Opal 1996). IL-1ra blocks the action of IL-1a and IL-1b functional ligands by competitive 
inhibition at the IL-1 receptor level. IL-1ra binds with equal or greater affinity than does IL-
1a and IL-1b to the type 1 (80 kd) membrane-bound IL-1 receptor. IL-1ra does not bind with 
high affinity to the type II (68 kd) IL-1 receptor (Dinarello, 1997; Simms et al., 1993). By 
occuping the receptor, IL-1ra prevent cellular activation by IL-1α or IL-1β. The anti-
inflammatory cytokines IL-4, IL-10, and IL-13 inhibit the synthesis of IL-1β, yet they 
stimulate the synthesis of IL-1ra.1 (Schreuder et al., 1997).  
IL-4, is a glycoprotein produced by mature Th2 cells and cells from the mast cell or basophil 
lineage and it is able to influence Th cell differentiation. IL-4 is an anti-inflammatory 
cytokines because it goes to block or suppress the monocyte-derived cytokines, including 
IL-1, TNF-a, IL-6, IL-8, and macrophage inflammatory protein (MIP)-1α (Opal and DePalo, 
2000; Brown and Hural, 1997; Paul, 1991). This cytokine also suppresses macrophage 
cytotoxic activity, parasite killing, and macrophage-derived nitric oxide production (Vannier 
et al., 1992), and stimulates the synthesis of the cytokine inhibitor IL-1ra (Hart et al., 1989). 
IL-10, which is the most important anti-inflammatory cytokine found within the human 
immune response. It is a potent inhibitor of Th1 cytokines, including both IL-2 and IFN-γ 
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(Opal and DePalo, 2000). IL-10 is primarily synthesized by CD41 Th2 cells, monocytes, and 
B cells and   inhibits monocyte/macrophage-derived TNF-α, IL-1, IL-6, IL-8, IL-12, 
granulocyte colony-stimulating factor, MIP-1α, and MIP-2α (Clark et al., 1998; Marchant et 
al., 1994). ,IL-10 promotes the development of a type 2 cytokine pattern by inhibiting the 
IFN-γ production of T lymphocytes (Romagnani, 1995), directly inhibited the proliferation 
of CD4+ T cells and production of cytokines such as IL-2, IFNγ, IL-4, IL-5, and TNF-α 
(Joss et al., 2000), consequently impairing cellular immune responses, and regulates 
Th1/Th2imbalance. IL-10 also reduces the secretion of IL-23 by macrophages, which is 
essential for the existence of Th17 cells (Llorente et al., 1995).   
IL-11 was initially described as a hematopoietic growth factor with particular activity in the 
stimulation of thrombopoiesis (Opal and DePalo, 2000); this anti-inflammatory cytokine has 
been shown to attenuate IL-1 and TNF synthesis from macrophages by up-regulating 
inhibitory NF-kB (inhibitory NF-kB) synthesis in monocyte/macrophage cell lines. 
Inhibitory NF-kB prevents NF-kB from translocating to the nucleus where NF-kB functions 
as a transcriptional activator for the proinflammatory cytokines (Trepicchio et  al, 1997). IL-
11 has also been shown to inhibit the synthesis of IFN-g and IL-2 by CD41 T cells.  
IL-13, is secreted by activated T lymphocytes; IL-13 and IL-4 share a common cellular 
receptor, and this accounts for many of the similarities between these two anti-inflammatory 
cytokines (Callard et al., 1996). The principal functional difference between IL-4 and IL-13 
lies in their effects on T cells. IL-4 is a dominant mediator of Th2 cell differentiation 
(Zurawski et al., 1994), whereas IL-13 has minimal effects on T-cell function. IL-13 can 
down-regulate the production of TNF, IL-1, IL-8, and MIP-1α by monocytes (Zurawski et 
al., 1994; de Waal Malefyt et al., 1993) and has profound effects on expression of surface 
molecules on both monocytes and macrophages (de Waal Malefyt et al., 1993). 
TGF-β is an important regulator of cell proliferation, differentiation, and formulation of the 
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extracellular matrix (Litterio and Roberts, 1997). Like many cytokines, TGF-b has both pro- 
and anti-inflammatory effects. It functions as a biological switch, antagonizing or modifying 
the action of other cytokines or growth factors (Opal and DePalo, 2000). In an inflammatory 
state, TGF-β is produced by macrophages upon their phagocytosis of apoptotic cells and 
exerts an anti-inflammatory eﬀect, reflecting a negative regulation of inflammation 
processes (Fadok et al., 1998).  It can convert an active site of inflammation into one 
dominated by resolution and repair (Litterio and Roberts, 1997). An isoform of TGF-β, 
TGF-β1, is capable of suppressing  the proliferation and differentiation of T cells and B cells 
and limits IL-2, IFN-g, and TNF production (Opal and DePalo, 2000).  
With the potential exception of interleukin (IL)-1 receptor antagonist (IL-1ra), all anti-
inflammatory cytokines have at least some pro-inflammatory properties as well (Opal and 
DePalo, 2000). For example, although the cytokine IL-6 can be also anti-inflammatory, in 
this work I will treat the argument considering its pro-inflammatory properties during 
neuroinflammation.  
 
 
1.3.1 Interleukin (IL)-6 
 
Interleukin-6 (IL-6) is one of the two cytokines that I studied and analyzed during this part 
of my PhD work. IL-6 is part of the family of cytokines that includes IL-11, leukemia 
inhibitory factor (LIF), oncostatin M (OSM), ciliary inhibitory factor (CNTF), cardiotropin-
1 (CT-1), cardiotrophin-like related cytokine and stimulating neurotrophin-1/B-cell 
stimulating factor 3 (NNT-1), neuropoietin (NPN), IL-27, and IL-31; with the exception of 
IL-31, all IL-6 type cytokines share the membrane glycoprotein gp130 as a common 
receptor and signal transducer subunit (Heinrich et al., 2003; Scheller et al., 2006). It was 
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originally discovered as a factor produced by lymphocytes that stimulated the final 
maturation of B cells to antibody-producing cells (Hirano et al., 1986). As I said, many 
cytokines have both pro- and anti-inflammatory properties and IL-6 is one of them; it was 
originally considered to be a pro-inflammatory cytokine, but several discoveries prompted a 
revision of its characteristics and indicated that IL-6 also has anti-inflammatory properties 
(Sporeen er al., 2011). For example, IL-6 inhibits neutrophil accumulation after LPS 
injectionand antagonizes the action of IL-1β and TNF-α via induction of the soluble IL-1 
receptor antagonist and the soluble TNF-α receptor (Tilg et al., 1994; Ulich et al., 1991). On 
the other hand, IL-6 is considered a proinflammatory cytokine acting in the initiation and 
coordination of inflammatory responses and limiting the spread of infectious agents; it helps 
to initiate and regulate acute-phase responses, a complex of adjustments in metabolic and 
executive organ functions (liver, immune cells) and circulating serum components that assist 
in host defense. CNS activities relate to fever induction, sleep, increased pain perception, 
reduced food intake, and neuroendocrine mobilization of energy stores (Hanisch, 2002). The 
tendency for one over the other net effect is likely determined by the simultaneous presence 
of other factors (like cytokines). IL-6 seems to be one of the most important cytokines in the 
CNS: a vast range of stimuli, varying from neurotransmitters over depolarization to other 
inflammatory cytokines, is able to induce IL-6 production in the brain (Sporeen et al., 2011).  
IL-6 belongs to a cytokine family of which all the members share a common signal 
transducer named gp130 (glycoprotein 130 or CD130). All the family members possess a 
similar tertiary structure, composed of 4 α-helices with an up-up-down-down topology. Of 
these members, several have a role in the CNS. The IL-6 family members bind to their 
respective membrane receptors and this binding leads to the dimerization of the signal-
transducer protein gp130 (Sporeen., 2011).  
The receptor complex mediating the biological activities of IL-6 consists of the IL-6 binding 
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type I transmembrane glycoprotein termed IL-6R (or CD126 or gp80) and the type I 
transmembrane signal transducer protein gp130. IL-6 first bind to the membrane-bound non-
signaling α-receptor IL-6R. Then, this complex binds to two molecules of gp130 and leads 
to IL-6-signal transduction, which includes activation of JAK/STAT, ERK, and PI3K signal 
transduction pathways (Scheller et al., 2011). Once recruited, the STATs (especially STAT3) 
are phosphorilated by JAKs and this induces dimerization of STATs and their subsequent 
translocation to the nucleus where they modulate gene transcription Sporeen et al., 2011).  
Some cytokines have soluble receptors, and they are important for the regulation of cytokine 
signaling (Scheller et al., 2011); IL-6 also has a soluble receptor, s IL-6r; this was 
discovered in urine and in plasma and is generated via either alternative splicing of  IL-6R 
mRNA (Lust et al., 1992), or shedding of the membrane receptor (Mullberg et al., 1993). 
This soluble receptor amplifies IL-6-mediated signaling by activation of cell types that 
express the signal transducer protein gp130 but lack mbIL-6R expression (Scheller et al., 
2011). Although gp130 is an ubiquitous protein, IL-6R expression is much more restricted. 
The generation of s IL-6R is a mechanism to conferring IL-6 responsiveness to cells lacking 
IL-6R (Spooren et al., 2011).  
 
 
1.3.1.1 IL-6 and neuroinflammation 
 
IL-6 is really important during neuroinflammation. Soon after its discovery, it was 
demonstrated that some astrocytoma and glioma lines expressed IL-6 when stimulated with 
IL-1β, which prompted speculation that IL-6 could have a role in the CNS (Yasukawa et al., 
1987; Erta et al., 2012). Later, it was discovered that both glial and neuronal cells expressed 
IL-6 and IL-6R to various degrees throughout the brain (Cornfield and Sills, 1991; Vallieres 
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and Rivest, 1997).  Besides neurons and glial cells, endothelial cells produce great amounts 
of IL-6, which can act on surrounding cells but also in an autocrine manner regulating a 
number of adhesion proteins but also IL-6 synthesis, particularly in the presence of sIL-6R 
(Jirik et al., 1989; Reyes et al., 1999).  
It is clear that IL-6 is an important cytokine in the CNS because many cytokines and 
inflammatory factors as well as neurotranmitters and neuropeptides have been shown to 
affect is regulation (Erta et al., 2012). For example, when microglia and astroglia are 
infected by a virus, they both secrete IL-6 (Frei et al., 1989; Righi et al., 1989);  IL-1β and 
TNFα induced IL-6 in cultured cortical neurons (Ringheim et al., 1995); the AMPc-PKA 
pathway may also induce astrocytic IL-6 (Norris et al., 1994; Cadman et al., 1994). IL-1β is 
a potent stimulator of IL-6 production in astrocytes (Lee et al., 1993); IFN-γ induces IL-6 
(and NO) in the murine microglial cell line 6-3 (Hashioka et al., 2007), this cytokine does 
not induce IL-6 in astrocytes unless it is coincubated with IL-1β (Benveniste et al., 1990). 
IL-17 functioned in a synergistic manner with IL-6 (+ sIL-6R) to induce IL-6 expression in 
astrocytes (Ma et al., 2010). These are some examples that explain the central role of the IL-
6 production in the CNS. There are dozens of other different pathways and stimuli that leads 
to its secretion.  
IL-6 is produced also in physiological conditions. For instance, they have an influence on 
neurons; in normal conditions IL-6 KO mice show a 60% reduction of the compound action 
potential of the sensory branch of the sciatic nerve and a dramatic decrease of temperature 
sensitivity in the frontpaw withdrawal time in the hot-plate assay; and IL-6 is also important 
for neuronal recovery after injury (Zhong et al., 1999). IL-6 also has a role in adult 
neurogenesis (Bauer et al., 2007; Deverman and Patterson, 2009), the process of creating 
new neurons and glial cells from neural stem cells (NSCs) (Erta et al., 2012).  
IL-6 has effect also on glia and endothelial cells: it seems that IL-6 could have proliferative 
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effects on astrocytes but in synergy with other factor (Levinson et al., 2000) while microglia 
in culture consistently proliferate when stimulated with IL-6 (Streit et al., 2000). Regarding 
oligodendrocytes, in addition to promoting oligondendrogenesis, IL-6 promotes survival and 
myelin production of oligodendrocytes (Valerio et al., 2002; Zhang et al., 2006; Pizzi et al., 
2004; Zhang et al., 2007).  
Besides, IL-6 stimulates the pituitary-adrenal axis (Navarra et al., 1992; Mastorakos e al., 
1993), induces fever (Schöbitz e al., 1995; Klir et al., 1993; Chai et al., 1996) and it is very 
important in the control of body temperature following recovery from stroke (Herrmann et 
al., 2003).  
CNS IL-6 is upregulated whenever neuroinflammation is expected, such as following CNS 
infection or injury or in a number of CNS diseases (Erta et al., 2012). Studies demonstrated 
that IL-6 was expressed and produced in CNS during viral meningitis, in encephalitis mouse 
models, and in CSF of patients with acute viral infections (Frei et al., 1988) and IL-6 was 
also found to be upregulated in mouse experimental cerebral malaria (ECM) (Grau et al., 
1990). IL-6 was highly found in CSF of patients with systemic lupus erithematosus (SLE) 
with CNS involvement (Hirohata and Miyamoto, 1990) or in those in advanced stages of 
patients with human immunodeficiency virus (Pagliusi et al., 1990) infections (Laurenzi et 
al., 1990). Two studies, where transcriptomic analysis of IL-6KO mice versus WT mice and 
that of GFAP-IL-6 mice were used in a model of brain cortex cryoinjury, revealed that IL-6 
modulates the expression of many genes involved in inflammation, apoptosis and oxidative 
stress among others (Poulsen et al., 2005; Quintana et al., 2008).  
IL-6 production is also altered in neurodegenerative disease, where there always is 
inflammation. So, its expression is elevated in brain areas surrounding amyloid plaques and 
in cerebrospinal fluid in the brains of Alzheimer’s disease (AD) patients (Bauer et al., 1991; 
Hampel et al., 2005). IL-6 also enhances neuronal damage induced by beta-amyloid peptide 
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in cultured rat cortical neurons (Qiu and Gruol, 2003). It has also been demonstrated the 
presence of IL-6 in acute and chronic active plaques of multiple sclerosis (MS) patients, 
mainly associated with astrocytes rather than macrophages or mononuclear infiltrating cells 
(Maimone et al., 1997). IL-6 seems to have a role also in Parkinson's disease (PD), because 
its level in the CSF of PD patients are elevated (Mogi et al., 1996). As regard another 
neurodegenerative disease, Huntington’s disease (HD), IL-6 expression was found to be 
dramatically elevated in the striatum of HD patients (Björkqvist et al., 2008).  
IL-6 is important for processes like astrogliosis and microgliosis. As regard the activation of 
astrocytes, it has been demonstrated that direct infusion of IL-6 in rat brain increases GFAP 
expression and leads to astrogliosis (Balasingam et al., 1994; Woiciechowsky et al., 2004); 
indirect delivery of IL-6 in the striatum also leads to astrogliosis (Tilgner et al., 2001).  
Furthermore, IL-6 -/-mice have impaired neuroglial activation and reduction of astrogliosis 
after injury (Klein et al., 1997). IL-6 activates astrocytes through the JAK-2/STAT-3 
pathway (Damiani and O'Callaghan, 2007; Sriram et al., 2004). The cytokine and this 
pathway seems to be implicated in driving astrogliogenesis (Bonni et al., 1997; He et al., 
2005).  
IL-6 affects astrocytes in multiple ways, influencing their proliferation, the secretion of 
inflammatory mediators and growth factors, astrocytic chemotaxis and astrogliogenesis 
(Sporeen et al., 2011). This cytokine induces a micro-RNA for the cyclin-dependent kinase 
inhibitor 2A (CDKN2A) in astrocytes and this allows down-regulation of the cell growth 
repressor CDKN2A and in this way the astrocytes can proliferate (Pogue et al., 2010). 
Moreover, astrocytes are induced by IL-6 to produce several other cytokines, chemokines, 
prostaglandins and acute phase proteins (Barnum et al., 1996; Bolin et al., 2005; Chikuma et 
al.,2009; Kordula et al 1998; Quintana et al., 2008; Sporeen et al., 2011). The stimuli that 
induce astrocytes to produce IL-6 are different: neurotransmitters (e.g. norepineprhine), 
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neuropeptides (e.g.vasoactive intestinal peptide, substance P), inflammatory cytokines (e.g. 
TNF-α, IL-1β and IL-6 itself) and viral and bacterial pathogens (e.g.LPS) (Sporeen et al., 
2011).  
IL-6 influences also the microglia and the process of microgliosis. In numerous studies, it 
has been seen the correlation between the overexpression of IL-6 and the enhanced 
microgliosis with astrogliosis, in vivo (Brunello et al., 2000; Chiang et al., 1994; Di Santo et 
al., 1996; Fattori et al., 1995); besides, it is possible to block the release of LPS-induced 
microgliosis by intracerebral injection of an anti-IL-6 antibody (Pang et al., 2006). IL-6 
stimulated also microglia proliferation in vitro (Streit et al., 2000).  
Finally, IL-6 seems to have an important role in controlling the integrity of the BBB, but not 
as a proinflammatory cytokine. In this case, IL-6 acts as an antiinflammatory cytokine, by 
helping to keep the integrity of the BBB during neuroinflammation (Milner and Campbell, 
2006).  
 
 
1.3.2 CXCL10 
 
I also analyzed another cytokine, the CXC motif chemokine 10 (CXCL10 or IP-10). 
CXCL10 is a  cytokine belonging to the CXC chemokine family. The chemokine family 
contains 48 structurally homologous chemotactic cytokines that induce leukocyte migration 
and activation by binding to seven transmembrane-spanning receptors shown to be coupled 
to pertussis toxin (PTX) sensitive Gai proteins (Klein, 2004). They are small secreted 
molecules that exhibit very specific cysteine motifs in their amino acid sequence. Most 
chemokines have four characteristic cysteines, and depending on the motif displayed by the 
first two cysteines, they have been classified into CXC or alpha, CC or beta, C or gamma, 
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and CX3C or delta chemokine classes (Rossi and Zlotnik, 2000).  These structural motifs 
bear functional differences in terms of chemoattraction for various leukocyte cell types and 
so, CXC chemokines may attract neutrophils or lymphocytes (Klein, 2004).  
CXCL10 is a IFN-γ-inducible chemokine; first, IFN-γ binds to the IFN-γ heterodimeric 
receptor that activates the JAK/STAT pathway, which leads to STAT1 activation, then 
STAT1 translocate to the nucleus and binds to the promoter region of immediate-early-IFN-
γ-inducible genes, leading to the transcription of CXCL10 (Bach et al., 1997). This 
chemokine is produced by monocytes and activated astrocytes (in particular after stimulation 
with viruses), endothelial cells and fibroblasts; also microglia produce CXCL10, after viral 
stimulation or during neurodegenerative diseases like Alzheimer's disease and multiple 
sclerosis (Xia et al., 2000). Its production is induced by IFN-γ, but CXCL10 has been 
observed to enhance IFN-γ release both in vitro and in vivo. Besides, it is involved in the 
development of antigen-driven T-cell responses, suggesting that this chemokine plays an 
important role in the overall evolution of Th1 peripheral immune responses (Gangur et al., 
1998; Hancock et al., 2001; Dufour et al., 2002).  
CXCL10 is also involved in neuronal apoptosis pathways via activation of CXCR3 by 
neurons. Previous studies demonstrated that treatment of CXCR3-expressing neurons with 
CXCL10 results in a caspase-3 dependent apoptotic cell death (Sui et al., 2006) and so, the 
chemokine required for the recruitment of effector immune cells by virally infected neurons 
for their survival might also promote their death (Durrant et al., 2014).  
CXCL10 has certainly a role in neuroinflammation, since it has been found in great amount 
in the SNC during infections and inflammations due to neurodegenerative diseases like 
Alzheimer's disease, multiple sclerosis (Xia et al., 2000) and prion disease (Tribouillard-
Tanvier et al, 2009).   Like cytokines, also chemokines can have a protective role within the 
CNS through their ability to orchestrate leukocyte entry and interactions at the endothelial 
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barriers of the CNS and initiate CNS repair of damaged tissue within the CNS, but at the 
same time, they can also enhance and promote the neuroinflammation and its detrimental 
effects. The pro or anti-inflammatory property of this chemokine seems to depend on the 
disease and on the contest; so, in many models of viral encephalitis induced by MHV, WND 
and HSV, CXCL10 has a beneficial role, helping to eliminate cells infected with viruses, in 
contrst, CXCL10-driven inflammation has detrimental effects in encephalitis induced by 
LCMV, malaria and trypanosomes (Michlmayr and McKimmie, 2014).  
In a study of Sui and colleagues, they used the SHIV/rhesus macaque model of HIV-E to 
investigate whether there was a link between CXCL10 overexpression and neuronal 
degeneration and they found that CXCL10 was overexpressed in neurons in the brains of 
individuals with HIV-E and that exogenous CXCL10 led to activation of caspase-3 and 
neuronal apoptosis (Sui et al., 2004).  
There are many works on the neuroprotective role of CXCL10, but at the same time, there 
are emerging studies about its detrimental effect, in particular on neurons. During 
neuroinflammation, it is very important for neuronal apoptosis, probably by calcium 
dysregulation (Sui et al., 2006). 
 
 
 
1.4 Prion diseases 
 
Among neurodegenerative diseases, there are prion diseases, which are disorders that affect 
both humans and animals (Prusiner 1991). They include scrapie (sheep and goats), bovine 
spongiform encephalopathy (cattle), chronic wasting disease (CWD in cervids) and 
Creutzfeldt-Jakob (CJD) in humans. They are caused by a conformational change of a host 
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protein, the PrP sen (protease-sensitive prion protein), also known as cellular PrP (PrPc). 
This protein is a host-encoded membrane glycoprotein 208 amino acids long expressed in 
many tissues and cell type and it is called protease sensitive because it is sensitive to 
digestion with proteinase K (PK) and detergent soluble.  
 
Fig.1Proteinase K resistance of PrP. A denaturing polyacrylamide gel electrophoresis with antibody 
staining is shown in left panel. ‘Full-length’ and N-terminal truncated PrP are presented in the right 
panel 
 
In Fig.1the Western blot of an SDS-gel electrophoresis of PrPC and PrPSc, without and with 
proteinase K digestionis shown. The three bands of PrP disappear completely after digestion 
with PK, while, as regards PrPSc, the bands remain nearly undiminished in intensity although 
shifted to lower molecular weight (Riesner, 2003). PrPSc from different species or prion 
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strains may show different degrees of protease resistance (Colby and Prusiner, 2011). PrP is 
posttranslationally processed to remove a 22-amino-acid, amino-terminal signal peptide and 
a 23-amino-acid, carboxyterminal peptide, which directs addition of the GPI anchor that 
tethers the protein to the cell membrane. No post-translational modifications to the primary 
structure differentiate PrPC from PrPSc (Stahl et al. 1993).  
The normal functions of PrP are not known although PrPnull mice have detectable deficits 
in both neurophysiological and memory functions (Aguzzi et al., 2008). The problem is 
when it changes its confomation becoming an abnormal protease-resistant disease-associated 
form (PrPres), also known as PrP scrapie (PrPSc) (Tribouillard-Tanvier et al., 2009). This 
form is PK resistent and this is in fact a way to distinguish and detect the presence of PrPres. 
This form of the protein is also insoluble and its accumulation in the brain is believed to be 
involved in the neurodegeneration which leads to the characteristic spongiform changes in the 
brains of infected animals (Brander et al., 2008). In the brains of some, but not all, animals 
and humans that have died of prion diseases, amyloid plaques are found which contain PrP, 
as determined by immunostaining and Edman protein sequencing studies (Roberts et al., 
1988; Tagliavini et al., 1991). PrPsen and PrPres have the same primary structure, having 
the same aminoacidic sequence, but different secondary structure: PrPsen has more alpha-
helices but during the formation of PrPres, PrPsen undergoes conformational changes that 
involve an increase of β-sheet secondary structure (Vorberg et al., 2001). Purified prions, 
either in the form of ‘full-length’ PrPSc or as PrP 27–30, are insoluble, even in mild 
detergents; in the brains of CJD or Kuru victims, PrP deposits can be detected as diffuse 
deposits, amyloidic fibres, condensed plaques, or florid plaques (Riesner, 2003). 
In order to uderstand how the PrPC form changes into PrPSc, many experiments have been 
carried out; for example, in  an experiment of Morillas and collegues, the PrPC-like, α-
helical state was established first as it is in the non-infected organism. Then the transition to 
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the PrPSc-like conformation was induced by slightly denaturing conditions. It was found 
that β-sheet formation is always connected with aggregation and that the most stable state, at 
least at acidic pH, is the β-sheet-rich aggregated state. Other studieson the in 
vitro conversion were carried out with natural PrP and at neutral pH  (Riesner et al., 
1996). Infectious PrP 27–30 was converted to an α-helical, oligomeric and non-infectious 
form by addition of 0.3% sodium-dodecylsulphate (SDS). These experiments were closest to 
natural conditions if the low concentrations of SDS were regarded as a membrane-like 
environment. It was also shown that the conversion occurs in steps, first fast formation of β-
sheet structure concomitant with forming small oligomers, then larger oligomers in minutes 
to an hour, and finally large insoluble aggregates in hours to days (Riesner, 2003).  
So, when the PrPSc takes contact with the PrPC, it induces its conformational change, leading 
to the conversion of the normal protein on infective prion protein. Prion propagation 
requires conversion of PrPC to PrPSc, thought to occur by a templateassisted process in 
which PrPSc acts as a template onto which PrPC is refolded into the infectious 
conformation . PrPC may need to enter a partially unfolded, intermediate state to interact 
with PrPSc and undergo conversion; this intermediate state is referred to as PrP (Cohen et al. 
1994). The conversion of PrPC to PrPSc may also require the assistance of one or more as-
yet-unidentified cofactors, provisionally designated protein X. Presumably, protein X binds 
to PrPC and enables it to interact with PrPSc for conversion (Colby and Prusiner, 2011).  
Prion diseases occur as sporadic, genetic, and transmissible disease in humans. Although 
infectious forms of prion disease are most well known to the general public, sporadic and 
heritable forms of the disease occur much more frequently in humans, with sporadic (s)CJD 
accounting for approximately 85% of cases (Colby and Prusiner, 2011). It seems that the 
cause of CJD is spontaneous misfolding of PrPC into PrPSc. Amyloid plaques are a 
nonobligatory feature of prion diseases. Approximately 10% of sCJD cases whereas 70% of 
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kuru cases show amyloid plaques; all vCJD cases show amyloid plaques surrounded by a 
halo of spongiform degeneration (Colby and prusiner, 2011).  
A prominent feature of neurodegenerative diseases like prion diseases is the early onset of 
gliosis in the brains of infected hosts. The direct cause of this gliosis is unclear, but evidence 
of microglial and astroglial activation coincides with the detection of disease-associated 
protease-resistant prion protein (PrPres). As I mentioned before, gliosis is an event that 
occurs after microglia and astrocytes activation and it can be caused by the cytokines 
produced by glia cells during these events.  
Na et al. detected phosphorylation of STAT1 and STAT3 in scrapie-infected mice, and it has 
been suggested that JAK2-STAT1 signaling may be important in facilitating astrogliosis 
during infection with scrapie strain ME7. This neuroinflammatory reaction appears to be a 
host response to PrPres accumulation and associated brain cell damage. However, this 
neuroinflammation might also act either to increase or to decrease prion disease 
pathogenesis, and if so, therapeutic intervention to increase or dampen this reaction might be 
beneficial (Tribouillard-Tanvier et al., 2012). 
Unfortunately, no treatment is currently available to halt the progression of any of these 
illnesses. Studies of prions in mice have elucidated several aspects of neurodegeneration that 
may prove useful in developing effective therapeutics.  
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1.5 Statins 
 
1.5.1 What are statins and what is their function? 
 
Fig. 2 Mevalonate pathway 
 
Statins are a class of drugs whose main action is to lower cholesterol levels, so they are 
principally used as therapeutics for the treatment of cardiovascular diseases. Cholesterol in 
synthesized from acetyl-CoA, through the mevalonate pathway (Fig.2), which is a series of 
enzymatic reactions that leads to the production of polyisoprenoids (e.g. dolichol) and 
sterols (e.g. lanosterol, ergosterol, cholesterol) in fungi, plant cytoplasm, animals, most other 
eukaryotes, archaea and some eubacteria (Miziorko, 2011). Statins goes to block the 
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production of cholesterol by inhibiting the enzyme HMG-CoA reductase (3-hydroxy-3-
methyl-glutaryl-CoA reductase), which is responsible for the reduction of HMG-CoA into 
Mevalonate: HMG-CoA reductase catalyses the rate-limiting step of cholesterol biosynthesis, 
a four electron reductive deacylation of HMG-CoA to CoA and mevalonate (Liao and Laufs, 
2005). Mevalonic acid, or Mevalonate, is the precursor of isoprenoids, a class of compounds 
involved in diverse cellular functions such as sterol synthesis and growth control. Within 
cells, the concentration of mevalonate is tightly controlled through the HMG-CoA (Istvan et 
al., 2000). The statins do more than just compete with the normal substrate in the enzymes 
active site. They alter the conformation of the enzyme when they bind to its active site. This 
prevents HMG-CoA reductase from attaining a functional structure (Stancu and Sima, 2001). 
By inhibiting the HMG-CoA reductase, all the pathway is inhibited and there is no 
cholesterol synthesis.  
The statin family is composed of eight unique compounds that are naturally derived or 
chemically synthesized (Wong et al., 2002). The common structural characteristic of all 
statins is a side chain that exists either in a closed ring (inactive, lactone) or an open ring 
(active, acid) form (Istvan et al., 2000; Istvan and Deinsenhofer, 2001). The open ring 
conformation of this drug blocks catalytically active HMG-CoA reductase by functioning as 
a molecular mimic of a reaction intermediate formed within the active site of this enzyme 
(Istvan and Deinsenhofer, 2001). The inhibition of this enzyme leads to a decrease in 
intracellular hepatic cholesterol levels which then induces expression of cell surface low-
density lipoprotein receptors, enabling cholesterol to be removed from the circulation and 
replenish intracellular cholesterol stores (Ucar et al., 2000).  
Although their action against hypercholesterolemia is the most important reason for their use 
as therapy, they seems to have other interesting effects. For example they has been tested as 
anti-cancer drugs: deregulated or elevated activity of HMGCoA reductase has been shown 
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in a range of different tumors and MVA pathway holds an important regulatory role in 
cellular proliferation and transformation, so statins has been used as antiproliferative to 
arrest cancer cells growth and to induce apoptosis in tumor-derived cells (Wong et al., 2002). 
They have been also used to reduce oxidative stress in patients with atherosclerotic 
cerebrovascular disease (statins had antioxidant effects against lipid peroxidation but not 
protein oxidation or DNA damage) (Moon et al., 2014).  
Statins have been used also to reduce the accumulation of α-synuclein (whose aggregation in 
the brain is a typical sign of diseases like dementia with Lewy bodies and Parkinson’s 
disease) and ameliorate the associated neuronal deficits, in the treatment of Parkinson's 
disease (Bar-On et al., 2008). Another neurodegenerative disease, Alzheimer's disease, has 
been treated with statins (Fassbender et al., 2001), since cellular cholesterol levels affect 
neuronal Aβ production in vitro and this protein is the main component of the amyloid 
plaques which accumulate in the brains of patients with Alzheimer's disease. Statins have 
been  also used to treat mice infected by prion proteins: for example, in 2008, Haviv and 
colleagues used prion disease as a model for progressive neurodegeneretion in order to test 
the effect of Simvastatin on prion disease progression, PrPSc levels and neurotoxic effects in 
mice infected with scrapie. They decided to use a statin, though, not for the pleiotropic 
effects of these drugs but to see if lowering the cholesterol level in the brain would have had 
some kind of effect of the interaction of PrPSc and PrPC ; they found that Simvastatin delayed 
disease progression and increased the survival of mice, but the beneficial effect of this drug 
was not correlated wih cholesterol level (Haviv et al., 2008). The same results were seen in 
two other works (Mok et al., 2006; Kempster et al., 2007). In another 2008 work, an italian 
group used Pravastatin to treat scrapie-infected mice and they found that high-dose and 
long-term oral Pravastatin treatment prolonged survival times of infected mice. They also 
reported that, although they were using an hydrophilic statin, this charactestic did not affect 
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the results (Vetrugno et al., 2008).  
Finally, statins have been used to treat the neuroinflammation caused by cerebral malaria 
(CM), effect due to their pleiotropic activity. In this study, they propose that drugs with 
pleiotropic effects on inflammation and metabolism could be ideal candidates to target 
neuroinflammation and decrease cognitive impairment after severe infectious syndromes 
and that statins may be such agents because they can modify two processes leading to brain 
injury: neuroinflammation and activation of proinflammatory microglia (Reis et al., 2012).  
 
 
1.5.2 Anti-inflammatory properties of statins 
 
There are many studies in which statins are thought to be good anti-inflammatory drugs, 
because of their pleiotropic effect and many groups are using them to inhibit inflammation 
due to infections.  
How statins may act as anti-inflammatory drugs? They can reduce systemic inflammation by 
lowering the proinflammatory tendencies of macrophages and neutrophils, by limiting 
endothelial cell activation, and by enhancing T-helper cell (Th)-1 function, all of this by 
influencing intracellular signaling (Terblanche et al., 2007). As I explained earlier, 
mevalonate is the precursor of many classes of sterol and non-sterol end-product, and among 
the non-sterol products there are numerous isoprenoid molecules, including farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate. They serve for the isoprenylation of 
proteins and it allows the subcellular localisation and intracellular traﬀcking of membrane-
associated proteins such as heterometric G-proteins, haem-a, nuclear lamins, and small 
GTP-binding proteins (Takemoto and Liao, 2001).  These proteins are important for 
intracellular inflammatory signaling because they modulate the response of various protein 
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kinases; so, when statins goes to inhibit the  HMG-CoA reductase and consequently the 
production of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, protein 
isoprenylation is slowed and this goes to influence the inflammatory response. For example, 
protein kinases activate the transcription factor nuclear factor kappa B (NKfB), which can 
be induced by bacteria and viruses and leads to the production of many cytokines. Statins 
can inhibit NkfB-associated signaling and consequently the production of inflammatory 
mediators (Terblanche et al., 2007). Also the mitogen-activated protein kinase (MAPK) 
family is part of the transcriptional regulation: these proteins are activated by 
proinflammatory cytokines like IL-1, TNF-α and LPS, and once activated they promote the 
production of more proinflammatory cytokines by monocytes and macrophages (Cuschieri 
et al., 2005; Lahti et al., 2003). So, also the inhibition of MAPK signaling brings to the 
reduction of proinflammatory mediators.  
An important study that addressed the anti-inflammatory effect of statins was the PRINCE 
(pravastatin inflammation/CRP evaluation) trial. This trial demonstrated that oral 
administration of pravastatin for 24 weeks significantly reduced serum CRP levels in 
subjects with and without CVD, independently of any changes in LDL cholesterol (Albert et 
al., 2001). This study confirmed the anti-inflammatory effects of pravastatin in the primary 
and secondary prevention setting.  
Usually, during inflammation, cytokines are not the only inflammatory molecules produced; 
many kind of cells produce also reactive oxygen species, leading to oxidative stress, which 
goes to worse the inflammatory situation. Different statins have been used successfully 
against these molecule, for example Hernandez-Perera and his group used two statins, 
Atorvastatin and Simvastatin to modulate the expression of the vasoactive factors ET-1 and 
NO and they showed that statins significantly reduce the synthesis of ET-1 and the 
expression of its precursor, the pre–proET-1 mRNA, in a process specifically related to the 
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inhibition of HMG-CoA reductase; they also observed that statins prevent the 
downregulation of eNOS mRNA and protein levels associated to oxLDL (Hernandez-Perez 
et al., 1998). Another interesting work that inspired my thesis was that of Pahan and 
colleagues, who used Lovastatin to inhibit the production of nitric oxide and cytokines in rat 
primary glia cells and macrophages (Pahan et al., 1997).  
Finally, statins inhibit interferon-γ-stimulated CIITA promoter IV expression in numerous 
human cells, including endothelial cells and monocytes/macrophages (Jacobson et al., 2005) 
and this inhibition is highly specific for the inducible form of MHC-II expression, and does 
not aﬀect MHC class I; so, statins can also modulate the adaptive immune system through 
the suppression of MHC-II expression by monocytes/macrophages (Terblanche et al., 2007).  
 
 
 
1.5.3 Statins used in this work 
 
Statins were originally discovered as secondary metabolites of fungi, the first statin 
discovered and used was mevastatin, which was isolated from Penicillium citrinium in 1976 
(Endo et al, 1976). When it was used on rats, it inhibited the cholesterol production but it 
had also toxicity effects on hepatocytes, so it was abandoned. Three years later, in 1979, 
another statin, Lovastatin, was isolated from Aspergillus terreus, resulting in a more active 
and less toxic compound than mevastatin. Now we have a great number of statins, both 
natural and chemically modified.  
Statins have different tissue permeability and because of that, they are classified into 
hydrophilic and lipophilic groups. Lipophilic statins are considered more likely to enter 
endothelial cells by passive diffusion than hydrophilic statins which are primarily targeted to 
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the liver (Liao and Laufs, 2005).  Moreover, not all statins are in an active form and 
consequently ready to use; most of them are already in the active form (with the open ring), 
while lovastatin and simvastatin need to be activated by hydrolisis which allows the opening 
of the ring. In vivo this process occurs in the liver, while in vitro it has be done with ethanol, 
NaOH, and heat.  
In my experiments for this part of my thesis, I used four different statins: Atorvastatin, 
Simvastatin, Lovastatin and Pravastatin. Three of these statins belong to the group of 
“lipophilic” statins (Atorvastatin, Simvastatin and Lovastatin ), while the other one is 
“hydrophilic” statin (Pravastatin).  
Atorvastatin 
Atorvastatin was synthesized in 1985 and it is a lipophilic compound. It was approved for 
use in the United States in 1996 and has become one of the most commonly prescribed 
drugs in America . Besides the cholesterol lowering effect, this statin was used also to 
reduce inflammation, for example it was assigned to 430 patients with acute coronary 
syndromes (ACS) (in a randomized, double-blind, placebo-controlled study) and it was seen 
an anti-inflammatory effect (Macin et al., 2005). Atorvastatin reduced the 
neuroinflammation in mice after injection of the amyloid-beta protein Aβ1–40 (Piermartiri et 
al., 2010). Experimental data have indicated that the treatment with atorvastatin for 1 week 
significantly reduced neurological deficits and increased the survival and synaptogenesis in 
the hippocampus after traumatic brain injury (Lu et al, 2004), suggesting neuroprotective 
effects.  
 
Simvastatin 
Simvastatin is more recent, it was developed in 1992 from Aspergillus terreus and it is a 
lipophilic molecule. Also Simvastatin has been used as an anti-inflammatory drug, for 
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example for treating the inflammation occurring with rheumatoid arthritis (RA), an 
autoimmune disease in which there is production of a great amount of proi-inflammatory 
cytokines (Leung et al., 2003). They showed that simvastatin can suppress murine collagen-
induced arthritis (CIA), either prophylactically, or if administered after clinically evident 
onset of disease. Pruefer and his group were the first to  demonstrate a protective effect of 
simvastatin under conditions of acute inflammation induced by an exotoxin within the 
microcirculation; in particular they proved that simvastatin is able to attenuate enhanced 
leukocyte-endothelium interaction after S aureus -toxin administration ( Pruefer et al., 2002). 
An example of the use of simvastatin on neuroinflammation is a work of 2006, in which 
Zeinstra and her collegues, on the theory that the development of autoimmune lesions in the 
central nervous system (multiple sclerosis) may be due to a failure of endogenous inhibitory 
control of MHC class II expression on astrocytes, allowing these cells to adapt an interferon 
(IFN)- γ-induced antigen presenting phenotype, and reporting that Statins have been shown 
to reduce MHC class II expression in cultured microglia (Youssef et al., 2002), used 
simvastatin on astrocytes cultures from newborn rats to inhibit up to 70% of IFN-γ-induced 
MHC class II expression (Zeinstra et al., 2006).  
Lovastatin 
As I already mentioned, Lovastatin is one of the first statins discovered, in 1979, from 
Aspergillus terreus; also Lovastatin has lipophilic characteristics. Lovastatin has been used 
to inhibit the production of nitric oxide and cytokines induced by LPS in rat primary glia 
cells and macrophages (Pahan et al., 1997). Moreover, in another study of 2014, a group 
investigated the effects of f lovastatin on mRNA expression of proinflammatory cytokines 
(interleukin-1β, tumor necrosis factor α, interleukin-6) and the antiinflammatory cytokine 
IL-10 in the hippocampus during epileptogenesis on rats, reporting that lovastatin decreases 
the inflammatory process in the hippocampus induced by long-lasting SE (Gouveia et al., 
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2014), after they showed, in another work, that t lovastatin is able to decrease the neuronal 
death rate induced by long-lasting status epilepticus (Gouveia et al., 2011).  
Pravastatin 
Pravastatin is the only hydrophilic molecule that I used; it is a derivative of compactin, 
which was identified in he fungus Penicillium citrinium in the 1970s (like mevastatin). It 
was used in clinical trials in healthy volunteers, showing to be effective for lowering LDL 
cholesterol with no severe side effects. After an interruption due to problems with compactin 
(it seems that it was seriuosly toxic on animals), the trials with lovastatin were started again 
in 1982 with good results on very high-risk patients (Tobert, 2003).  
Also pravastatin seems to have anti-inflammatory properties in addition to its principal 
function of cholesterol-lowering drug. For example, in a study of 2003, its anti-
inflammatory properties were tested on 50 patients with type 2 diabetes; they finally found 
that pravastatin reduces levels of coagulation and inflammation markers in type 2 diabetic 
patients(Sommeijer et al., 2004). However, there are not many studies, in particular as 
regard a possible anti-inflammatory and neuro-protective property during 
neuroinflammation. For this reason, it could be interesting to try also this statin in my 
experiments.  
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2. AIM OF THE PROJECT 
 
Since statins seems to have anti-inflammatory and neuroprotective activities besides their 
principal role as cholesterol-lowering drugs, during this part of my PhD I used four different 
statins (Atorvastatin, Simvastatin, Lovastatin and Pravastatin) to inhibit the production of 
pro-inflammatory cytokines (IL-6 and CXCL10) in vitro. In order to do this, I used cortical 
astrocyes and microglia primary cultures from newborn C57BL/10SnJ mice and Sprague-
Dawley rats, which I stimulated with LPS to recreate a situation of neuroinflammation. 
Statins were used to inhibit the production of cytokines, stimulated by the activation with 
LPS.  
Future projects at NIH-LPVD laboratories contemplate the use of statins to inhibit the 
neuroinflammation in vivo, on mice infected by prion diseases.  
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RESULTS AND DISCUSSION 
 
3.1 Immunofluorescent staining 
For my experiments, pure primary cell culture of astrocytes and microglia were needed; it is 
nearly impossible to have a 100% pure culture but usually, with the protocol used in this 
work to separate a mixed glia cell culture it is possible to obtain a culture with > 90% of 
purity.  
The aim of the fluorescent staining was to determine the purity of the cell culture. This 
technique was  used every time different conditions were introduced, such as different type 
of cells or separation method or different animal, to verify if the procedure used was 
successful. Fig.1  reports  an example of the staining for mice and rats cells: the fig.1a 
represents a well of a chamber slide in which astrocytes from mice brains were seeded (after 
the separation procedure) and stained with the antibody α-GFAP (in red), which goes to bind 
to the GFAP on astrocytes. This allows to put in evidence the astrocytes in the wells and 
also their morphology. The cells were stained also with DAPI, which is a blue fluorescent 
stain that binds to the DNA, thus allowing to put in evidence the nuclei and to distinguish 
the cells from any debris. As can be seen from the picture, the most part of the nuclei match 
to the cells highlighted by the antibody GFAP; furthermore, the cells have typical astrocyte 
morphology and the color of the dye appear to be very bright; this indicates that most of the 
cells in the picture are effectively astrocytes and so, the culture was almost completely pure. 
There are some cells which are not surrounded by the red dye: they are probably microglia. 
It s normal to have some other type cells, mostly microglia, also after the separation since it 
is very difficult to separate completely these two kind of glia cells. In fig.1b there is the 
picture of well of a chamber slide in which microglia from mice brains were seeded and 
stained with the antibody α-IBA-1 specific for microglia (in green) and DAPI (in blue). Also 
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in this case, the purity of the culture was very high, as can be deduced from the brightness of 
green dye which put in evidence microglia and from the high matching between nuclei 
stained with DAPI and green cells. Most of the cells are microglia. In both cases there are 
not many cells, but it is normal since the cells are incubated in chamber slides for almost 
three days and usually mice cells grow very slowly in vitro, especially microglia. Figures 
from 1g to 1h, report pictures of rat glia cells; this time there are single pictures of cells 
stained with an antibody and then a picture where the first two are merged, to see the 
matches between the two dyes. Figures from 1c to 1e represent cells from rat brains; in 
particular they are pictures of the same well in which astrocytes from rat brains were seeded: 
in 1c it is possible to observe cells stained with the antibody α-GFAP while in 1d there are 
the same cells stained with DAPI; in fig.1e there are the two pictures merged. First af all, in 
this case it is possible to observe that there are more cells than that in mice astrocyte culture 
and this is because rat cells grow very easily and faster than mice cells in vitro. Also in this 
case the cells in red are almost completely matching to the nuclei in blue, meaning that most 
of them are astrocytes and also in this case the separation procedure was successful, even 
though it was used a different time for shaking for rat cells, almost 18 hours vs 4 hours used 
for mice cells. This prolonged time period could bring to the detachment of astrocytes from 
the surface of the flasks, but it did not ever occurred.  
Finally, figures from 1f to 1h represent the same well in which rat microglia were seeded; in 
1f it is possible to observe cells stained with the antibody α-IBA-1 while in 1g there are the 
same cells stained with DAPI; in fig. 1h there are the two pictures merged. As for mouse 
microglia, even though rat microglia grow in a greater number, they are however less than 
astrocytes, mainly because of their slow growth. As can be seen in fig. 1h, they are mainly 
microglia.  
In this work, it is reported only an example for each case, but this staining procedure was 
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repeated every time different conditions were used, always obtaining similar results. 
Therefore, the cultures used in the experiments hada very few contamination by other type 
of cells, which would not constitute a problem for the results of the stimulations.  
 
 
 
 
 
 
Fig.1 (a) Chamber slide containing mouse astrocytes cell culture, in which the cells have been 
stained with α-GFAP and DAPI; (b) Chamber slide containing mouse microglia cell culture, in 
which the cells have been stained with α-IBA-1 and DAPI; (c) Chamber slide containing rat 
astrocytes cell culture, cells stained with DAPI; (d) same chamber, in which the cells have been 
stained with α-GFAP; (e) merged images, α-GFAP+DAPI; (f) Chamber slide containing rat 
microglia cell culture, cells stained with DAPI; (g) same chamber, in which the cells have been 
stained with IBA-1; (h) merged images, α-IBA-1+DAPI. 
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3.2 Inhibition of cytokines production with statins 
 
To see if statins could be helpful in the inhibition of neuroinflammation, it was stimulated 
the activation and production of cytokines in glia cells from newborn C57BL/10SnJ mice 
and Sprague-Dawley rats. After obtaining cortical astrocytes and microglia cell culture, 
these cells were stimulated with lipopolysaccharide (LPS); in order to decide the 
concentration for the best stimulation similar experiments described in literature were 
considered, in which the same cells and the same stimulant were used and it was also 
performed a LPS curve to see which concentration would have the best stimulation and a 
higher production of cytokines; this LPS curve was performedusing a different kind of cell 
every time, using 10 different concentrations of LPS, with a dilution of 1:10 (data not 
shown). Based on these experiments and on literature, for the first experiments on mouse 
cells 1 ng/ml of LPS were used; after some experiments, though,1 µg/ml of LPS were 
prefered because of the poor stimulation.  
With LPS stimulation, the cells were activated and they produced cytokines, thanit was tried 
the inhibition with the use of 4 statins, at different concentrations and dilutions. After 20 
hours, the supernatant was collected and on this, the Extracellular protein kit (BIOPLEX) 
was used to determine the presence and the eventual inhibition of two pro-inflammatory 
cytokines, CXCL10 and IL-6.  
In the following paragraphs the production and inhibition of these two cytokines in different 
types of cells will be analyzed. 
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3.2.1 Inhibition of the production of CXCL10 in mouse astroglia 
 
 
Fig.2. Graphs of 4 experiments on stimulation of mouse astroglia with 1 ng/ml of LPS and 
inhibition of CXCL10 production with Atorvastatin 10 µM.  
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Fig.3. Graphs of 4 experiments on stimulation of mouse astroglia with 1 ng/ml of LPS and 
inhibition of CXCL10 production with Simvastatin 5 µM (a-b) and 10 µM (c-d). 
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Fig.4. Graph on stimulation of mouse astroglia with 1 µg/ml of LPS and inhibition of CXCL10 
production with Pravastatin 10 µM. 
 
These graphs represent the first experiments in which it was analyzed the inhibition of the 
production of the pro-inflammatory chemokine CXCL10 by activated mouse cortical 
astrocytes. On these type of cells Atorvastatin and Simvastatin were tested four times and 
Pravastatin one time. As it has been mentioned before, it was used 1 ng/ml of LPS to 
stimulate the cells. In each experiment  different concentrations of statins were used, in 
order to verify if there could be a dose-dependent response. thus, in the graphs it is reported 
only the highest concentration used 10 or 5 µM; in each graph there is the control, which is 
constituted by cells and medium as negative control. In addition, statin alone was used as a 
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control, to see if statins could activate cells and to see any possible toxicity on cells with the 
MTT assay. As regard the experiments with Atorvastatin, using 1 ng/ml of LPS it has been 
always obtained a good stimulation, especially in the third and last experiment (Fig.2.3 and 
2.4) but there was a significant reduction of CXCL10 production only in the first (Fig.2.1) 
and third (Fig.2.3) experiment.  
In the experiments with Simvastatin (Fig.3) there is a very similar situation. Also in this case 
it was used 1 ng/ml of LPS with a good stimulation. In the last two experiments (Fig.3.3 and 
3.4) 10 mM of Simvastatin instead of 5 µM but the inhibition seems to follow the same 
trend regardless of the concentration of the drug used.  
Finally, Pravastatin was used in one experiment. There is not much literature about the anti-
inflammatory property of Pravastatin, especially on possible neuroprotective effects so it 
was decided to try it on mouse astrocytes but this drug had no effects on CXCL10 
production.  
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3.2.2 Inhibition of the production of IL-6 in mouse astroglia 
 
Fig.5. Graphs of 2 experiments on stimulation of mouse astroglia with 1 ng/ml and 1 µg/ml of LPS 
and inhibition of IL-6 production with Atorvastatin 10 µM.  
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Fig.6. Graph on stimulation of mouse astroglia with 1 µg/ml of LPS and inhibition of IL-6 
production with Simvastatin 5 µM. 
 
 
 
Fig.7. Graphs of 2 experiments on stimulation of mouse astroglia with 1 ng/ml  of LPS and 
inhibition of IL-6 production with Lovastatin 10 µM.  
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Together with the experiments on CXCL10 the statins were tested also on the production of 
the other pro-inflammatory cytokines like IL-6. For this reason, also in this case the 
conditions can vary (concentrations of LPS or statins). As regard IL-6 production by mouse 
astrocytes, three statins were , Atorvastatin, Simvastatin and Lovastatin. Atorvastatin was 
used in two experiments: the drug was always used starting from 10 µM in both cases, while 
as regards LPS, in the first experiment (Fig.5.1) the cells were stimulated with 1 ng/ml of 
LPS, obtaining a good stimulation but not as good as in CXCL10 experiments, so it was 
decided to use more LPS (1 µg/ml) in the second experiment (Fig.5.2), but it was not 
successful; plus, it was obtained an inhibition of cytokine production only the first time. 
Also Lovastatin was used two times at the concentration of 10 µM (Fig.7.1-2), using two 
concentration of LPS, but it was never obtained any inhibition. Simvastatin was used only in 
one experiment (Fig.6) at the concentration of 5 µM but with no inhibition of IL-6.  
 
3.2.3 Inhibition of the production of IL-6 in mouse microglia 
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Fig.8. Graphs of 2 experiments on stimulation of mouse microglia with 1 µg/ml  of LPS and 
inhibition of IL-6 production with Atorvastatin 10 (8.1) and 30 µM (8.2).  
 
  
Fig.9. Graphs of 2 experiments on stimulation of mouse microglia with 1 ng/m1 and µg/ml of LPS 
and inhibition of IL-6 production with Lovastatin 10 (9.1) and 30 µM (9.2).  
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Fig.10. Graph on stimulation of mouse microglia with 1µg/ml of LPS and inhibition of IL-6 
production with  30 µM of Simvastatin.  
 
In this work also microglia were used in order to verify the production of IL-6 since these 
cells are the major producers of this cytokine and since they are the cells that are primarily 
activated during neuroinflammation. On this type of cells Atorvastatin, Lovastatin and 
Simvastatin were used. As regards Atorvastatin, it has been used for the inhibition in two 
experiments, after a stimulation of microglia with 1 µg/ml of LPS; in the first experiment 
(Fig.8.1) it was used 10 µM of statin but there was no inhibition, probably because there was 
not stimulation too. In the second experiment (Fig.8.2) it was increased the concentration of 
Atorvastatin (30 µM), having a successful stimulation and inhibition of cytokine production. 
I wss also used Lovastatin two times: in the first experiment (Fig.9.1) it was used less LPS 
(1 ng/ml) and 10 µM having no stimulation and inhibition, while the second time (Fig.9.2) 
they were increased both, resulting in a good stimulation and inhibition of IL-6. Finally 
Simvastatin was tried using directly the highest concentration of LPS and statin and there 
was also in this case a good stimulation and a successful inhibition of IL-6 (Fig.10).  
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3.2.4 Inhibition of the production of IL-6 in rat astroglia 
 
Fig.11. Graphs on stimulation of rat astrocytes with 1 µg/ml of LPS and inhibition of IL-6 
production with 30 µM of Atorvastatin.  
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Fig.12. Graphs on stimulation of rat astrocytes with 1µg/ml of LPS and inhibition of IL-6 
production with 30 µM of Lovastatin.  
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At a certain pointalso rat glia cells have been used, since the results with mouse cells were 
not fully satisfying yet and there was the possibility that statins would work better with rats, 
since most of the works in literature are on experiments with rat cells. We started with rat 
cortical astroglia, using two statins, Atorvastatin and Lovastatin. For the stimulation it was 
used 1 µg/ml of LPS and for the inhibition it was used 30 uM for both statins. In both cases 
three experiments were performed. Unfortunately,  rats astroglia never reached a good 
stimulation and they never produced a sufficient amount of IL-6, so it is very difficult to 
understand if statins could inhibit its production; in fact, with Atorvastatin (Fig.11) There 
was never any inhibition, while, in Lovastatin case, it could be some inhibition in the second 
experiment (Fig.12.2) but the third experiment (Fig.12.3) did not confirm the result. In the 
first experiments of both statins (Figs. 12-13(1-4)), in the samples with LPS and statins there 
is a higher stimulation than that in the samples with LPS alone.   
 
3.2.5 Inhibition of the production of IL-6 in rat microglia 
Fig.13. Graphs on stimulation of rat microglia with 1µg/ml of LPS and inhibition of IL-6 
production with 30 µM of Atorvastatin.  
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Fig.14. Graph on stimulation of rat microglia with 1µg/ml of LPS and inhibition of IL-6 production 
with 30 µM of Simvastatin. 
 
Fig.15. Graph on stimulation of rat microglia with 1µg/ml of LPS and inhibition of IL-6 production 
with 30 µM of Lovastatin.  
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On rat microglia experiments in total were performed, of which two experiments were on 
Atorvastatin (Fig.13.1-13.2), one on Simvastatin (Fig.14) and one on Lovastatin (Fig.15). In 
every experiment the same conditions and concentrations for stimulation and inhibition 
(1µg/ml of LPS and 30 uM of statin) were used. Unfortunately,  rat microglia have never 
been stimulated and for this reason the inhibition was impossible to obtain.  
 
 
 
 
CXCL10 fluorescence (mouse microglia) 
Pretreatment Average+SD 
LPS 
Average+SD 
ATV+LPS 
Average+SD 
SIM+LPS 
Average+SD 
PVS+LPS 
8 hours 1833.5 +130 497.25 +222 1006.25 +227 - 
8 hours 1488 +121 1505 +209 1770.5 +634 - 
8 hours 3200.5 +204 2605 +570 1816 + 238 - 
8 hours 2540.4 +122 2716.8 + 268 2358.5 +58 - 
8 hours 2151.5 +133 - - 1759.8 + 274 
 
Tab.1 Summary table of the experiments on the production of CXCL10 with mouse astroglia. 
 
IL-6 fluorescence (mouse astroglia) 
Pretreatment Average+SD 
LPS 
Average+SD 
ATV+LPS 
Average+SD 
SIM+LPS 
Average+SD 
LOV+LPS 
8 Hours 1087.12 + 
77.1 
143.37 +137 930.5 +122 - 
8 Hours 555.3 +261 - - 944.17 +143 
8 Hours 277.25 +287.4 265.5 +226.3 - 54.16 +85.6 
 
Tab.2 Summary table of the experiments on the production of IL-6 with mouse astroglia. 
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IL-6 fluorescence (mouse microglia) 
Pretreatment Average+SD 
LPS 
Average+SD 
ATV+LPS 
Average+SD 
SIM+LPS 
Average+SD 
LOV+LPS 
8 Hours 343.9 +11 (ATV 10 
uM) 223 +30 
- (LOV 10 
uM) 158 +36 
8 Hours 976.55 + 96 247.3 +27.7 268.1 +129 250 +64 
 
Tab.3 Summary table of the experiments on the production of IL-6 with mouse microglia. 
 
IL-6 fluorescence (rat astroglia) 
Pretreatment Average+SD 
LPS 
Average+SD 
ATV+LPS 
Average+SD 
SIM+LPS 
Average+SD 
LOV+LPS 
8 Hours 189 +126.7 411.3 +186.7 - 595.7 +99.4 
8 Hours 381.5 +39 275.6 +4.1 - 209 +42.4 
8 Hours 45.1 +5.5 33.25 +12.3 - 167.1 +23.6 
 
Tab.4 Summary table of the experiments on the production of IL-6 with rat astroglia. 
 
IL-6 fluorescence (rat microglia) 
Pretreatment Average+SD 
LPS 
Average+SD 
ATV+LPS 
Average+SD 
SIM+LPS 
Average+SD 
LOV+LPS 
8 Hours 169.1 +44.5 69.6 +25.3 90.6 +29.5 - 
8 Hours 114.4 +41.2 97.4 +21.7 - 62.7 +36.1 
 
Tab.5 Summary table of the experiments on the production of IL-6 with rat microglia. 
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3.3 MTT Assay 
After removing the supernatant, the cells in the plate were used to performe an MTT Assay. 
This assay exploits the capacity of mitochondrial dehydrogenase to reduce the MTT to an 
insoluble purple formazan which is then solubilized and whose quantity is determined 
spectrophotometrically. Since only living, active cells can do this reduction, the MTT Assay 
is generally used to determine the cell viability. This assay was used to verify any possible 
cytotoxic activity of statins. I started to use this assay late, so unfortunately it was not 
performed on each experiment. For the procedure, see the chapter “Materials and methods”. 
 
 
3.3.1 MTT Assay on Inhibition of the production of IL-6 in mouse astroglia 
 
 
Fig.16. Graph of MTT assay on stimulation of mouse astrocytes with 1 ng/ml of LPS and inhibition 
with 10 µM of Lovastatin. 
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The cells were tested for their viability late, so for mouse astroglia it can be shown only the 
results of a MTT Assay on one of the last experiment, in which it was used Lovastatin (for 
the inhibition graph, see Fig.16 ). Both the wells in which the cells were treated with the 
statin or he LPS show absorance very similar to that of the control, meaning that they were 
not toxic in any way. There seems to be lower viability in  the wells were I performed the 
inhibition with LPS and statin though, as if they are exerting some kind of synergism and 
they result toxic together for the cells. 
 
3.3.2 MTT Assay on Inhibition of the production of IL-6 in mouse microglia 
 
Fig.17. Graph of MTT assay on stimulation of mouse microglia with 1 ng/ml (17.1) or 1 µg/ml (17.2) of 
LPS and inhibition with 10 µM (17.1) or 30 µM (17.2) of Atorvastatin.  
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Fig.17. Graph of MTT assay on stimulation of mouse microglia with 1 ng/ml (17.1) or 1 µg/ml (17.2) 
of LPS and inhibition with 10 µM (17.1) or 30 µM (17.2) of Atorvastatin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.18. Graph of MTT assay on stimulation of mouse microglia with 1 ng/ml (18.1) or 1 µg/ml (18.2) 
of LPS and inhibition with 10 µM (18.1) or 30 µM (18.2) of Lovastatin. 
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Fig.19. Graph of MTT assay on stimulation of mouse microglia with 1 µg/ml of LPS and inhibition 
with 30 µM of Simvastatin. 
 
In this case the MTT assay was perfomed on every experiment with mouse microglia. As 
regards Atorvastatin, in the first experiment of inhibition (Fig.17.1), the cells were not 
stimulated very well by 1 ng/ml of LPS and there was not inhibitionalso, so in the second 
experiment (Fig.17.2) I was used more LPS, having a good stimulation and inhibition. The 
graphs of MTT assay show that it is  possible that in the first experiment there was not any 
stimulation because the cells were not grown or it can be that most of them were already 
dead. In fact, in the second experiment were there was stimulation and inhibition, the reason 
could be that there was a good viability. The situation is very similar for Lovastatin. In fact, 
also in this case, in the first experiment (Fig.18.1) the lack of stimulation and inhibition 
could be due to the great amount of mortality of the microglia, while in the second 
experiment (Fig.18.2) they grew and they were stimulated by LPS. In this case, though, the 
MTT assay suggest that the inhibition of IL-6 production seen in Fig 9.2, could be due to a 
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possible cytotoxity of the statin, because in the wells were the cells were treated with 30 mM 
of Lovastatin (Fig.9.2), the viability is lower than that of the control and it is very similar to 
that of the wells in which the cells were stimulated with LPS and inhibited with Lovastatin. 
Finally, on cells treated with Simvastatin it was performed only an MTT assay (Fig.19) and, 
as for Lovastatin, also Simvastatin seems to be toxic for  mouse microglia.  
 
 
3.3.3 MTT Assay on Inhibition of the production of IL-6 in rat astrocytes 
  
 
Fig.20. Graph of MTT assay on stimulation of rat astrocytes with 1 µg/ml of LPS and inhibition 
with 30 µM of Atorvastatin. 
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Fig.21. Graph of MTT assay on stimulation of rat astrocytes with 1 µg/ml of LPS and inhibition 
with 30 µM of Lovastatin. 
 
On rat astrocytes three inhibition experiments were perfomed using atorvastatin, but the 
MTT assay was perfomed only on two of them. In the experiments in which this statin was 
used, there were never any stimulation by LPS and consequently any inhibition by this statin. 
If we consider the graphs of MTT assay (Fig.20.1-20.2), this situation could be explained 
with a low viability or growth of rat astrocytes (though, when observed at the microscope 
prior to the experiments, the cells formed a monolayer on the bottom of the plate). This 
situation occurred also in the case of Lovastatin (Fig. 21.1-21.2).  
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3.3.4 MTT Assay on Inhibition of the production of IL-6 in rat microglia 
 
Fig.22. Graph of MTT assay on stimulation of rat microglia with 1 µg/ml of LPS and inhibition 
with 30 µM of Atorvastatin. 
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Fig.23. Graph of MTT assay on stimulation of rat microglia with 1 µg/ml of LPS and inhibition 
with 30 µM of Simvastatin. 
 
 
Fig.24. Graph of MTT assay on stimulation of rat microglia with 1 µg/ml of LPS and inhibition 
with 30 µM of Lovastatin. 
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The last type of cells used were rat microglia. As regards the experiments of stimulation and 
inhibition of IL-6, good results were never obtained on these cells, with any statin; there was 
never stimulation and consequently inhibition of the cytokine. Looking at the MTT graphs, 
it is clear that statins or LPS do not have any toxic activity but, as for rat astrocytes, there 
was a low number of cells and maybe this fact could be the reason why the experiments on 
these cells never worked. Another reason could be that the LPS concentration was not 
sufficient for a good stimulation. 
 
 
MTT Assay (mouse astroglia) 
Pretreatment Average+SD 
O.D. 
Control 
Average+SD 
O.D. ATV 
Average+SD 
O.D. SIM 
Average+SD 
O.D. LOV 
8 Hours 0.96 + 0.03 - - (LOV 10 
uM) 0.87 + 
0.06 
 
Tab.6 Summary table of the experiments of cell viability on mouse astroglia 
 
MTT Assay (mouse microglia) 
Pretreatment Average+SD 
O.D. 
Control 
Average+SD 
O.D. ATV 
Average+SD 
O.D. SIM 
Average+SD 
O.D. LOV 
8 Hours 0.29 +0.04 (ATV 10 
uM) 0.19 
+0.03 
- (LOV 10 
uM) 0.16 
+0.02 
8 Hours 0.46 +0.02 0.32 +0.05 0.3 +0.04 0.33 + 0.05 
 
Tab.7 Summary table of the experiments of cell viability on mouse microglia 
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MTT Assay (rat astroglia) 
Pretreatment Average+SD 
O.D. 
Control 
Average+SD 
O.D. ATV 
Average+SD 
O.D. SIM 
Average+SD 
O.D. LOV 
8 Hours 0.25 +0.025 0.275 +0.03 0.34 +0.006 0.3 +0.007 
8 Hours 0.27 +0.03 0.17 +0.02 - 0.3 +0.03 
 
Tab.8 Summary table of the experiments of cell viability on rat astroglia 
 
MTT Assay (rat microglia) 
Pretreatment Average+SD 
O.D. 
Control 
Average+SD 
O.D. ATV 
Average+SD 
O.D. SIM 
Average+SD 
O.D. LOV 
8 Hours 0.32 +0.02 0.08 +0.008 0.24 +0.03 - 
8 Hours 0.21 +0.04 0.24 +0.03 - 0.2 +0.02 
 
Tab.9 Summary table of the experiments of cell viability on rat microglia 
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4. CONCLUSIONS 
 
There are many studies, especially in recent years, about neuroinflammation and its role in 
infectious and neurodegenerative disease, because it has become clear that 
neuroinflammation is part of the process that brings to the degeneration of the central 
nervous system. Here, the cells that have a central role in this process are glia cells, 
especially astrocytes and microglia. In fact, when a trauma or a pathogen hits the brains, 
these cells are activated, generating a number of processes including the production and 
secretion of pro-inflammatory cytokines.  
The most important role of cytokines is to stimulate other types of cells to produce chemical 
mediators of inflammation, which are responsible for the inflammatory response (Pontieri 
G.M., 2012).  There are a great number of cytokines with different roles; most of them have 
both pro and anti-inflammatory activity but for this project  only pro-inflammatory 
cytokines were studied. In particular, I focused on two cytokines, IL-6 and CXL10.  
Statins are a class of drugs whose main action is to lower cholesterol levels, so they are 
principally used as therapeutics for the treatment of cardiovascular diseases, but in the last 
few years, this type of drugs seems to have other properties, like anti-inflammatory 
properties, and for this reason, they have already been tested in a number of infectious and 
neurodegenerative diseases (Bar-On et al., 2008; Fassbender et al., 2001; Reis et al., 2012).   
Thus, during this part of my PhD I used four different statins (Atorvastatin, Simvastatin, 
Lovastatin and Pravastatin) to inhibit the production of two pro-inflammatory cytokines, IL-
6 and CXCL10, after stimulating cortical astrocyes and microglia primary cultures from 
newborn C57BL/10SnJ mice and Sprague-Dawley rats with LPS.  
From the results of these experiments, I would assume that the more interesting statins are 
Atorvastatin, Simvastatin and Lovastatin, while Pravastatin was used only at the beginning 
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with no results. This confirm the fact that Pravastatin is not often used for this purpose 
because, Pravastatin has anti-inflammatory properties but there are not many studies about a 
neuro-protective effect during neuroinflammation. So, after using Pravastatin in an 
experiment to try to inhibit the production of CXCL10 with no result it has been decided to 
focus on the other three statins that generally show more activity on different diseases.  
Under different conditions for stimulation and inhibition, as two different concentrations of 
LPS and different concentrations and dilutions of statins, the best results were obtained with 
1 µg/ml of LPS and 30 µM of statins for mouse cells. As regards rat cells, when the LPS 
curve was performed on rat microglia and astrocytes, the concentration of LPS that would 
give the best production of IL-6 seemed to be 1 µg/ml as for mice; moreover, in literature 
this seems to be the most used concentration. For example, in a work of 2014, Villa and her 
group stimulated primary microglia mouse cells with 1 µg/ml of LPS, having a great 
stimulation (Villa et al., 2014). Unfortunately,in my hands there was never any stimulation 
of either microglia and astrocytes, with this amount of LPS. From the viability assays 
(MTT), and from direct observation under the microscope prior to the experiments, the cells 
were not affected in terms of numbers and morphology, but it is possible that this type of 
cells need higher concentration of LPS to be stimulated. So, although statins have been used 
on rat cells before, I was not able to determine the optimal conditions to test statins. 
Better results were obtained with mouse cells, especially with microgliain which, when the 
appropriate conditions of stimulation and treatment were determined, a moderate inhibition 
of IL-6production was observed. Unfortunately, I did not have enough time left in the US to 
confirm this hypothesis. Based on the results of my preliminary experiments in the mouse 
model, indicating that statins inhibit the inflammation by acting on glia cells, in vivo testing 
of the effect of Atorvastatin and Simvastatin in mice affected by scrapie are ongoing.  
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5. MATERIALS AND METHODS 
 
5.1 Cell cultures 
Astroglia and microglia primary cells from 2 days old mice and Sprague-Dawley rats were 
used in these experiments. The use of 1- to 2-d-old pups ensures the absence of viable 
neurons in the cell suspension obtained from dissociating the cerebral cortex. The 
procedures used for these two types of cells and animals were very similar. It is not 
necessary to work in sterile conditions but it must be always used 70% ethanol to clean all 
the materials like surgical scissors, smooth fine forceps and flat tip forceps.  
The animals were sacrificed by rapid decapitation using the scissors. After removing the 
head, perform a midline incision, posterior to anterior, along the scalp to reveal the skull, 
then cut the cranium carefully from the neck to the nose. Using the flat tip forceps, the skull 
was opened and  the brain was removed , then it was placed in a Petri dish with PBS and ice. 
For the experiments cortical cells were needed, so, first the olfactory bulbs and the 
cerebellum were removed using dissecting forceps, then the two hemispheres were divided 
and a second set of forceps was used to the created grove and peel away the plate-like 
structure of the cortex from the brain. Finally the meninges were removed, in order to avoid 
contamination by meningeal astrocytes and fibroblasts. The cortex hemispheres were 
transferred in a 15 ml tube containing 4 ml of DMEM with no FBS in it. For rats, I put one 
brain in each tube, while for mice I put 3 or 4 brains in each tube.  
1 ml of 0.05% trypsin was added in each tube, the cells were then triturated by pipetting and 
the tubes were placed in the incubator at 37ºC for 10 minutes. Then the brains were 
centrifuged for 5 minutes at 800 rpm and re-suspended in 5 ml of fresh medium (DMEM 
with 10% FBS, 1% Pen/Strep, 1% L-Glutamate). This suspension was finally put in flasks 
(for rats I used T75 flasks containing 5 ml of suspension and 15 ml of DMEM, for mice I 
used T25 flasks containing 5 ml of suspension and 5 ml of DMEM). The flasks were 
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incubated at 37ºC, 5% CO2, for 10-13 days (generally, 10 days for rats and 13 days for mice 
cells).  
After this time period, generally the cells were confluent but they were a mixed cortical cell 
culture; so, in order to obtain astrocytes and microglia pure cell cultures, the cells needed to 
be separated. The separation procedure is based on the fact that, when shaken, astrocytes 
tend to stay adherent to the surface of the flask, while microglia detach from the flask and go 
in the suspension. So, the flasks with mixed glia cells were put in a shaker at 37ºC, 500 rpm, 
for 4-18 hours (4 h for mice cells, 18 hours for rats cells); then, microglia in the suspension 
were taken, centrifugated for 5 minutes, re suspended in fresh DMEM and seeded in 96 well 
plates at the density of 50000 cells/well. As regard astrocytes, they were detached from the 
flask using 1 ml of trypsin, then re-suspended in fresh DMEM and seeded in 96 well plates 
at the density of 50000 cells/well. The plates were put in an incubator at 37ºC, 5% CO2 for 3 
days.  
I also seeded 400 µl of cell suspension in a chambered slide in order to perfom a fluorescent 
staining procedure.  
 
5.2 Immunofluorescent staining 
In order to stain the cells cultures contained in the chambered slides I used the following 
protocol: 
• Remove the medium and wash the cells 3 times with PBS, in order to remove any trace of 
medium and dead cells; 
• Wash the cells 3 times with PBS; 
• Fix the cells with 3.7% formaldehyde for 15 minutes; 
• Wash the cells 3 times with PBS; 
• Permeabilize the cells with0,1% Triton X-100 for 10 minutes; 
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• Wash the cells 3 times with PBS; 
• Block with 3% BSA (bovine serum albumin) for 30 minutes; 
• Wash the cells 3 times with PBS; 
• Block with 0.2 M Glycine in PBS for 30 minutes; 
• Wash the cells 3 times with PBS; 
• Incubation with primary antibody for 1 hour (for astrocytes I used αGFAP 1:2500, for 
microglia I used αIBA-1 1:1000); 
• After 1 hour of incubation, wash the cells 3 times with PBS; 
• Incubation with secondary antibody for 1 hour ( for astrocytes I used α-rabbit AlexaFluor-
568 1:5000, for microglia I used α-rabbit AlexaFluor-488 1:5000); 
• Wash the cells 3 times with PBS; 
• After removing the chambers, put a drop of Prolong Gold Antifade with DAPI on cells, 
followed by a coverslip.; 
• Observe with fluorescence microscope. 
 
5.3 Reagents 
Lipopolysaccharide (LPS), Atorvastatin (ATV), Simvastatin (SIM), Lovastatin (LOV) and 
Pravastatin (PVS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). It was used a 
LPS stock of 1 mg/ml prepared in PBS and stored at -80°C. The stock of Atorvastatin and 
Pravastatin were prepared in DMSO, at the concentration of 10 µM and stored at -20ºC; as 
regard Simvastatin and Lovastatin, they need to be activated prior to use in experiments; the 
activation allows the opening of the lactone ring: 8 mg of SIM were dissolved in 0.2 ml of 
100% ethanol (19 µM), then  0.3 ml of 0.1 N NaOH were added. The solution was heated at 
50ºC for 2 h and then neutralized with HCl to pH 7. Finally I brought to a final volume (1 ml) 
with distilled water, and stored at −20°C until use. Similar protocol was used for a 10 µM 
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stock of Lovastatin: 25 mg of the lactone form weredissolved in 500 µl of 100% ethanol, 
heated to 50°C, alkalinized by adding 250 µl of 0.6 M NaOH, and incubated at 50°C for 2 h. 
After incubation, the solution was neutralized with 0.4 M HCl at pH 7.5 and stored at -20ºC 
(Morimoto et al., 2006). 
For immunofluorescence primary and secondary antibodies were used. For astrocytes I used 
α-GFAP as primary antibody (dilution 1:2500) and α-rabbit AlexaFluor-568 as secondary 
antiboby (dilution 1:5000); for microglia I used αIBA-1 as primary antibody (dilution 
1:1000) and α-rabbit AlexaFluor-488 as secondary antibody (dilution 1:5000).  
 
5.4 Induction of cytokines production 
Prior to stimulation with LPS, the cells were pretreated with different concentrations of 
statins for 8 hours, preparing the dilutions and putting 50 µl of each dilution in the wells. 
Then, the plate were put in the incubator for 8 hours. After that, the cells were stimulated to 
produce cytokines with LPS (at the concentration of 1x10-6 or 1x10-3 mg/ml), 50 µl/well. In 
the wells containing the control for the LPS 50 µl of LPS  and 50 µl of DMEM were seeded; 
in the wells where the cells were stimulated with LPS and treated with statins, 50 µl of LPS 
and 50 µl of the proper statin dilution were seeded. The wells containing the negative 
controls had 100 µl of DMEM. For the experiments it was always used DMEM without FBS. 
Then, the plates were incubated at 37ºC, 5% CO2 for 24 hours. After the incubation period 
the supernatant was taken for the analysis of cytokines, while the cells were used for the 
MTT assay.  
 
5.5 Determination of the inibition of cytokines production 
To determine if the treatment with statins could inhibit the production of cytokines by 
mouse and rat cell cultures, the Exracellular protein kit specific for mouse IP-10 or IL-6 and 
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for rat IL-6 (Bioplex), purchased from Invitrogen (Carlsbad, CA, USA) for Luminex® 
Platform was used.  
24 hours after stimulation with LPS and treatment with statins, I took the supernatant and I 
used the kit I mentioned above specific for the cytokine I wanted to analyzed, using the 
following protocol provided by the company: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fluorescence of each sample was finally read using the Luminex® Detection System.  
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5.6 MTT Assay 
In order to see if the treatment with statins could influence the cell viability, the MTT assay 
was performed on the cells, after removing the supernatant (which I used for the Bioplex 
Assay). In the first experiments the Vybrant® MTT Cell Proliferation Assay Kit purchased 
from ThermoFisher Scientific was used. This kit contained MTT 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (Component A), 10 vials, each containing 5 mg and 
SDS sodium dodecyl sulfate (Component B), 10 vials, each containing 1 mg; then it was 
used the MTT powder (ThermoFisher Scientific) which was dissolved in PBS (5mg/ml) and 
DMSO (dimethylsulfoxide) instead of the Component B to read the absorbance of the wells.  
Immediately after removing the supernatant, 100 μl of DMEM without phenol red (as this 
could interfere with the reading of the absorbance) were put in each well, plus 10 μl of MTT 
solution. The plates were incubated at 37ºC for 4 hours. During this incubation period the 
MTT is reduced to an  insoluble purple formazan product by mitochondrial dehydrogenase; 
after the incubation the formazan in dissolved with the component B or the DMSO and the 
absorbance is finally quantified spectrophotometrically, at 540 nm if using component B or 
at 570 nm if using DMSO.  
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